Document:

EX-10.2

 Exhibit 10.2 

AURA BIOSCIENCES, INC. 

2018 EQUITY INCENTIVE PLAN 
  

	1.	 DEFINITIONS. 

Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Aura Biosciences, Inc. 2018 Equity
Incentive Plan, have the following meanings: 
 Administrator means the Board of Directors, unless it has delegated power to act on
its behalf to the Committee, in which case the Administrator means the Committee. 
 Affiliate means a corporation which, for purposes
of Section 424 of the Code, is a parent or subsidiary of the Company, direct or indirect. 
 Agreement means an agreement between
the Company and a Participant delivered pursuant to the Plan and pertaining to a Stock Right, in such form as the Administrator shall approve. 

Board of Directors means the Board of Directors of the Company. 

Cause means, with respect to a Participant (a) dishonesty with respect to the Company or any Affiliate, (b) insubordination,
substantial malfeasance or nonfeasance of duty, (c) unauthorized disclosure of confidential information, (d) breach by a Participant of any provision of any employment, consulting, advisory, nondisclosure,
non-competition or similar agreement between the Participant and the Company or any Affiliate, and (e) conduct substantially prejudicial to the business of the Company or any Affiliate; provided, however,
that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in effect at the time of such termination, shall supersede this definition with
respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company. 

Code means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto.

 Committee means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or
pursuant to the provisions of the Plan. 
 Common Stock means shares of the Company’s common stock, $0.00001 par value per share.

 Company means Aura Biosciences, Inc., a Delaware corporation. 

Consultant means any natural person who is an advisor or consultant that provides bona fide services to the Company or its Affiliates,
provided that such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the Company’s or its Affiliates’ securities. 

Disability or Disabled means permanent and total disability as defined in Section 22(e)(3) of the Code. 

Employee means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an
officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. 

Fair Market Value of a Share of Common Stock means: 
  

	 	(i)	 If the Common Stock is listed on a national securities exchange or traded in the
over-the-counter market and sales prices are regularly reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the
composite tape or other comparable reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; 

 

	 	(ii)	 If the Common Stock is not traded on a national securities exchange but is traded on the over-the-counter market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked prices for the
Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter market for the
trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; and 

 

	 	(iii)	 If the Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the Administrator, in good faith, shall determine. 

ISO means an option intended to qualify as an incentive stock option under Section 422 of the Code. 

Non-Qualified Option means an option which is not intended to qualify as an ISO. 

Option means an ISO or Non-Qualified Option granted under the Plan. 

 Participant means an Employee, director or Consultant of the Company or an Affiliate
to whom one or more Stock Rights are granted under the Plan. As used herein, “Participant” shall include “Participant’s Survivors” where the context requires. 

Plan means this Aura Biosciences, Inc. 2018 Equity Incentive Plan. 

Securities Act means the Securities Act of 1933, as amended. 

Shares means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital
stock into which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.

 Stock Grant means a grant by the Company of Shares under the Plan. 

Stock Right means a right to Shares or the value of Shares of the Company granted pursuant to the Plan — an ISO, a Non-Qualified Option or a Stock Grant. 
 Survivor means a deceased Participant’s legal
representatives and/or any person or persons who acquired the Participant’s rights to a Stock Right by will or by the laws of descent and distribution. 
  

	2.	 PURPOSES OF THE PLAN. 

The Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates
in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to promote the success of the Company or of an Affiliate. The Plan provides for the
granting of ISOs, Non-Qualified Options or Stock Grants. 
  

	3.	 SHARES SUBJECT TO THE PLAN.

 (a) The number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i) 2,943,764
shares of Common Stock and (ii) any shares of Common Stock that are represented by awards granted under the Company’s 2009 Amended and Restated Stock Option and Restricted Stock Plan that are forfeited, expire or are cancelled without
delivery of shares of Common Stock or which result in the forfeiture of shares of Common Stock back to the Company on or after December 12, 2018, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has
interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 24 of this Plan. 

 (b) If an Option ceases to be “outstanding”, in whole or in part (other than by
exercise), or if the Company shall reacquire (at not more than its original issuance price) any Shares issued pursuant to a Stock Grant, or if any Stock Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares not
being issued, the unissued or reacquired Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing, if a Stock Right is exercised, in whole or in part,
by tender of Shares or if the Company or an Affiliate’s tax withholding obligation is satisfied by withholding Shares, the number of Shares deemed to have been issued under the Plan for purposes of the limitation set forth in Paragraph 3(a)
above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the net number of Shares actually issued. However, in the case of ISOs, the foregoing provisions shall be subject to any limitations under the Code.

  

	4.	 ADMINISTRATION OF THE PLAN. 

The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the
Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to: 

(a) Interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable
for the administration of the Plan; 
 (b) Determine which Employees, directors and Consultants shall be granted Stock Rights; 

(c) Determine the number of Shares for which a Stock Right or Stock Rights shall be granted; 

(d) Specify the terms and conditions upon which a Stock Right or Stock Rights may be granted; 

(e) Make changes to any outstanding Stock Right, including, without limitation, to reduce or increase the exercise price or purchase price,
accelerate the vesting schedule or extend the expiration date, provided that no such change shall impair the rights of a Participant under any grant previously made without such Participant’s consent; 

(f) Buy out for a payment in cash or Shares, a Stock Right previously granted and/or cancel any such Stock Right and grant in substitution
therefor other Stock Rights, covering the same or a different number of Shares and having an exercise price or purchase price per share which may be lower or higher than the exercise price or purchase price of the cancelled Stock Right, based on
such terms and conditions as the Administrator shall establish and the Participant shall accept; and 
 (g) Adopt any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax or other laws applicable to the Company, any Affiliate or to
Participants or to otherwise facilitate the administration of the Plan, which sub-plans may include additional restrictions or conditions applicable to Stock Rights or Shares issuable pursuant to a Stock
Right; 

 provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made
and prescribed in the context of not causing any adverse tax consequences under Section 409A of the Code and preserving the tax status under Section 422 of the Code of those Options which are designated as ISOs. Subject to the foregoing,
the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition,
if the Administrator is the Committee, the Board of Directors may take any action under the Plan that would otherwise be the responsibility of the Committee. 

To the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities
and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board of Directors or the Committee may revoke any such allocation or delegation at any time.

  

	5.	 ELIGIBILITY FOR PARTICIPATION. 

The Administrator will, in its sole discretion, name the Participants in the Plan; provided, however, that each Participant must be an
Employee, director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize the grant of a Stock Right to a person not then an Employee, director or
Consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or prior to the time of the execution of the Agreement
evidencing such Stock Right. ISOs may be granted only to Employees who are deemed to be residents of the United States for tax purposes. Non-Qualified Options and Stock Grants may be granted to any Employee,
director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under
any other benefit plan established by the Company or any Affiliate for Employees, directors or Consultants. 
  

	6.	 TERMS AND CONDITIONS OF OPTIONS.

 Each Option shall be set forth in writing in an Option Agreement, duly executed by the Company and, to the extent
required by law or requested by the Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions specifically required under this Plan, as the
Administrator may deem appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the following terms and conditions:

 (a) Non-Qualified Options: Each Option intended to be a
Non-Qualified Option shall be subject to the terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards for
any such Non-Qualified Option: 
  

	 	(i)	 Exercise Price: Each Option Agreement shall state the exercise price (per share) of the Shares covered
by each Option, which exercise price shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of Common Stock on the date of grant of the Option. 

	 	(ii)	 Number of Shares: Each Option Agreement shall state the number of Shares to
which it pertains. 

  

	 	(iii)	 Option Periods: Each Option Agreement shall state the date or dates on which it first is exercisable and
the date after which it may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain conditions or the attainment of stated goals
or events. 

  

	 	(iv)	 Option Conditions: Exercise of any Option may be conditioned upon the Participant’s execution of a
Share purchase agreement in form satisfactory to the Administrator providing for certain protections for the Company and its other shareholders, including requirements that: 

The Participant’s or the Participant’s Survivors’ right to sell or transfer the Shares may be restricted; and 

The Participant or the Participant’s Survivors may be required to execute letters of investment intent and must also acknowledge that the
Shares will bear legends noting any applicable restrictions. 
 (b) ISOs: Each Option intended to be an ISO shall be issued only to
an Employee who is deemed to be a resident of the United States for tax purposes, and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator determines are appropriate but not in
conflict with Section 422 of the Code and relevant regulations and rulings of the Internal Revenue Service: 
  

	 	(i)	 Minimum standards: The ISO shall meet the minimum standards required of
Non-Qualified Options, as described in Paragraph 6(a) above, except clause (i) thereunder. 

  

	 	(ii)	 Exercise Price: Immediately before the ISO is granted, if the Participant owns, directly or by reason of
the applicable attribution rules in Section 424(d) of the Code: 

  

	 	A.	 10% or less of the total combined voting power of all classes of stock of the Company or an Affiliate,
the exercise price per share of the Shares covered by each ISO shall not be less than 100% of the Fair Market Value per share of the Common Stock on the date of grant of the Option; or 

	 	B.	 More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, the
exercise price per share of the Shares covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common Stock on the date of grant of the Option. 

 

	 	(iii)	 Term of Option: For Participants who own: 

 

	 	A.	 10% or less of the total combined voting power of all classes of stock of the Company or
an Affiliate, each ISO shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement may provide; or 

  

	 	B.	 More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, each
ISO shall terminate not more than five years from the date of the grant or at such earlier time as the Option Agreement may provide. 

  

	 	(iv)	 Limitation on Yearly Exercise: The Option Agreements shall restrict the amount of ISOs which may become
exercisable in any calendar year (under this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO is granted) of the stock with respect to which ISOs are exercisable for the
first time by the Participant in any calendar year does not exceed $100,000. 

  

	7.	 TERMS AND CONDITIONS OF STOCK
GRANTS. 

 Each Stock Grant to a Participant shall state the principal terms in an Agreement duly executed by
the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be
appropriate and in the best interest of the Company, subject to the following minimum standards: 
 (a) Each Agreement shall state the
purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law, if any,
on the date of the grant of the Stock Grant; 
 (b) Each Agreement shall state the number of Shares to which the Stock Grant pertains; and

 (c) Each Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant,
including the time and events upon which such rights shall accrue and the purchase price therefor, if any. 

	8.	 [INTENTIONALLY OMITTED]. 

 

	9.	 EXERCISE OF OPTIONS AND ISSUE
OF SHARES. 

 An Option (or any part or installment thereof) shall be exercised by giving written
notice to the Company or its designee (in a form acceptable to the Administrator, which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph for the Shares as to which
the Option is being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to
the Administrator), shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which such
Option is being exercised shall be made (a) in United States dollars in cash or by check, or (b) at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative
accounting treatment) having a Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised, or (c) at the discretion of the Administrator, by
having the Company retain from the Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares as to which the Option
is being exercised, or (d) at the discretion of the Administrator (after consideration of applicable securities, tax and accounting implications), by delivery of the grantee’s personal recourse note bearing interest payable not less than
annually at no less than 100% of the applicable Federal rate, as defined in Section 1274(d) of the Code, or (e) at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage
firm, and approved by the Administrator, or (f) at the discretion of the Administrator, by any combination of (a), (b), (c), (d) and (e) above or (g) at the discretion of the Administrator, by payment of such other lawful
consideration as the Administrator may determine. Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO as is permitted by Section 422 of the Code. 

The Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the
Participant’s Survivors, as the case may be). In determining what constitutes “reasonably promptly,” it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law
or regulation (including, without limitation, state securities or “blue sky” laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery, be fully paid, non-assessable Shares. 
 The Administrator shall have the right to accelerate the date of exercise of any
installment of any Option; provided that the Administrator shall not accelerate the exercise date of any installment of any Option granted to an Employee as an ISO (and not previously converted into a
Non-Qualified Option pursuant to Paragraph 27) without the prior approval of the Employee if such acceleration would violate the annual vesting limitation contained in Section 422(d) of the Code, as
described in Paragraph 6(b)(iv). 

 The Administrator may, in its discretion, amend any term or condition of an outstanding
Option provided (i) such term or condition as amended is permitted by the Plan, (ii) any such amendment shall be made only with the consent of the Participant to whom the Option was granted, or in the event of the death of the Participant,
the Participant’s Survivors, if the amendment is adverse to the Participant, and (iii) any such amendment of any Option shall be made only after the Administrator determines whether such amendment would constitute a
“modification” of any Option which is an ISO (as that term is defined in Section 424(h) of the Code) or would cause any adverse tax consequences for the holder of any Option including, but not limited to, pursuant to Section 409A
of the Code. 
  

	10.	 ACCEPTANCE OF STOCK GRANTS AND
ISSUE OF SHARES. 

 A Stock Grant (or any part or installment thereof) shall be
accepted by executing the applicable Agreement and delivering it to the Company or its designee, together with provision for payment of the purchase price, if any, in accordance with this Paragraph for the Shares as to which such Stock Grant is
being accepted, and upon compliance with any other conditions set forth in the applicable Agreement. Payment of the purchase price for the Shares as to which such Stock Grant is being accepted shall be made (a) in United States dollars in cash
or by check, or (b) at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) and having a Fair Market Value equal as of the date of
acceptance of the Stock Grant to the purchase price of the Stock Grant, or (c) at the discretion of the Administrator (after consideration of applicable securities, tax and accounting implications), by delivery of the grantee’s personal
recourse note bearing interest payable not less than annually at no less than 100% of the applicable Federal rate, as defined in Section 1274(d) of the Code, or (d) at the discretion of the Administrator, by any combination of (a), (b) and
(c) above; or (e) at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. 

The Company shall then, if required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant was
accepted to the Participant (or to the Participant’s Survivors, as the case may be), subject to any escrow provision set forth in the applicable Agreement. In determining what constitutes “reasonably promptly,” it is expressly
understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or “blue sky” laws) which requires the Company to take any
action with respect to the Shares prior to their issuance. 
 The Administrator may, in its discretion, amend any term or condition of an
outstanding Stock Grant or applicable Agreement provided (i) such term or condition as amended is permitted by the Plan, (ii) any such amendment shall be made only with the consent of the Participant to whom the Stock Grant was made, if
the amendment is adverse to the Participant, and (iii) any such amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the Participant, including, but not limited to,
pursuant to Section 409A of the Code. 

	11.	 RIGHTS AS A SHAREHOLDER. 

No Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock
Right, except after due exercise of the Option or acceptance of the Stock Grant or as set forth in any Agreement, and tender of the aggregate exercise or purchase price, if any, for the Shares being purchased pursuant to such exercise or acceptance
and registration of the Shares in the Company’s share register in the name of the Participant. 
  

	12.	 ASSIGNABILITY AND TRANSFERABILITY OF STOCK
RIGHTS. 

 By its terms, a Stock Right granted to a Participant shall not be transferable by the Participant
other than (i) by will or by the laws of descent and distribution, or (ii) as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right may be transferred by a Participant for
value. Notwithstanding the foregoing, an ISO transferred except in compliance with clause (i) above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the
Administrator and in such form as the Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above, a Stock Right shall only be exercisable or may only be accepted, during the
Participant’s lifetime, by such Participant (or by his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or
similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a
Stock Right, shall be null and void. 
  

	13.	 EFFECT ON OPTIONS OF TERMINATION
OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY. 

Except as otherwise provided in a Participant’s Option Agreement, in the event of a termination of service (whether as an Employee,
director or Consultant) with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply: 
 (a) A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 14, 15, and 16,
respectively), may exercise any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only within such term as the Administrator has designated in a Participant’s Option
Agreement. 
 (b) Except as provided in Subparagraph (c) below, or Paragraph 15 or 16, in no event may an Option intended to be an ISO,
be exercised later than three months after the Participant’s termination of employment. The provisions of this Paragraph, and not the provisions of Paragraph 15 or 16, shall apply to a Participant who subsequently becomes Disabled or dies after
the termination of employment, director status or consultancy; provided, however, in the case of a Participant’s Disability or death within three months after the termination of employment, director status or consultancy, the Participant or the
Participant’s Survivors may exercise the Option within one year after the date of the Participant’s termination of service, but in no event after the date of expiration of the term of the Option. 

 (c) Notwithstanding anything herein to the contrary, if subsequent to a Participant’s
termination of employment, termination of director status or termination of consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent to the Participant’s termination, the Participant
engaged in conduct which would constitute Cause, then such Participant shall forthwith cease to have any right to exercise any Option. 

(d) A Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary
disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated
such Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide; provided, however, that, for ISOs, any leave of absence granted by the
Administrator of greater than three months, unless pursuant to a contract or statute that guarantees the right to reemployment, shall cause such ISO to become a Non-Qualified Option on the date that is six
months following the commencement of such leave of absence. 
 (e) Except as required by law or as set forth in a Participant’s Option
Agreement, Options granted under the Plan shall not be affected by any change of a Participant’s status within or among the Company and any Affiliates, so long as the Participant continues to be an Employee, director or Consultant of the
Company or any Affiliate. 
  

	14.	 EFFECT ON OPTIONS OF TERMINATION
OF SERVICE FOR CAUSE. 

 Except as otherwise provided in a Participant’s Option
Agreement, the following rules apply if the Participant’s service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all his or her outstanding Options have been
exercised: 
 All outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause
will immediately be forfeited. 
 Cause is not limited to events which have occurred prior to a Participant’s termination of service,
nor is it necessary that the Administrator’s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant’s termination of service but prior to the exercise of an Option, that either prior or
subsequent to the Participant’s termination the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited. 
  

	15.	 EFFECT ON OPTIONS OF TERMINATION
OF SERVICE FOR DISABILITY. 

 Except as otherwise provided in a Participant’s
Option Agreement: 
 (a) A Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of
Disability may exercise any Option granted to such Participant: 
  

	 	(i)	 To the extent that the Option has become exercisable but has not been exercised on the date of the
Participant’s termination of service due to Disability; and 

	 	(ii)	 In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of the Participant’s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days
accrued in the current vesting period prior to the date of the Participant’s termination of service due to Disability. 

(b) A Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant’s termination
of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all of the Shares on a later date if the Participant had not become Disabled and had continued to be an Employee, director
or Consultant or, if earlier, within the originally prescribed term of the Option. 
 (c) The Administrator shall make the determination
both of whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such
determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. 

 

	16.	 EFFECT ON OPTIONS OF DEATH
WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT. 

Except as otherwise provided in a Participant’s Option Agreement: 

(a) In the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate,
such Option may be exercised by the Participant’s Survivors: 
  

	 	(i)	 To the extent that the Option has become exercisable but has not been exercised on the date of death; and

  

	 	(ii)	 In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant’s
date of death. 

 (b) If the Participant’s Survivors wish to exercise the Option, they must take all
necessary steps to exercise the Option within one year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the Shares on a later date if he or she had not
died and had continued to be an Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option. 
  

	17.	 EFFECT OF TERMINATION OF SERVICE
ON UNACCEPTED STOCK GRANTS. 

 In the event of a termination of
service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason before the Participant has accepted a Stock Grant, such offer shall terminate. 

For purposes of this Paragraph 17 and Paragraph 18 below, a Participant to whom a Stock Grant has been offered and accepted under the Plan who
is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any
such absence, be deemed, by virtue of such absence alone, to have terminated such Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide. 

In addition, for purposes of this Paragraph 17 and Paragraph 18 below, any change of employment or other service within or among the Company
and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. 

 

	18.	 EFFECT ON STOCK GRANTS OF
TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY. 

Except as otherwise provided in a Participant’s Stock Grant Agreement, in the event of a termination of service (whether as an Employee,
director or Consultant), other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 19, 20, and 21, respectively, before all forfeiture provisions or Company rights of repurchase shall have lapsed,
then the Company shall have the right to cancel or repurchase that number of Shares subject to a Stock Grant as to which the Company’s forfeiture or repurchase rights have not lapsed. 

 

	19.	 EFFECT ON STOCK GRANTS OF
TERMINATION OF SERVICE FOR CAUSE. 

 Except as otherwise
provided in a Participant’s Stock Grant Agreement, the following rules apply if the Participant’s service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause: 

(a) All Shares subject to any Stock Grant that remain subject to forfeiture provisions or as to which the Company shall have a repurchase right
shall be immediately forfeited to the Company as of the time the Participant is notified his or her service is terminated for Cause. 

 (b) Cause is not limited to events which have occurred prior to a Participant’s
termination of service, nor is it necessary that the Administrator’s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant’s termination of service, that either prior or subsequent to the
Participant’s termination the Participant engaged in conduct which would constitute Cause, then all Shares subject to any Stock Grant that remained subject to forfeiture provisions or as to which the Company had a repurchase right on the date
of termination shall be immediately forfeited to the Company. 
  

	20.	 EFFECT ON STOCK GRANTS OF
TERMINATION OF SERVICE FOR DISABILITY. 

 Except as
otherwise provided in a Participant’s Stock Grant Agreement, the following rules apply if a Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture
provisions or the Company’s rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions
or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant through the date of Disability as would have lapsed had the Participant not become Disabled. The proration shall be based upon the number of days
accrued prior to the date of Disability. 
 The Administrator shall make the determination both as to whether Disability has occurred and
the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall
be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. 
  

	21.	 EFFECT ON STOCK GRANTS OF DEATH WHILE AN
EMPLOYEE, DIRECTOR OR CONSULTANT. 

 Except as otherwise provided in a
Participant’s Stock Grant Agreement, the following rules apply in the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or
the Company’s rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall
lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant through the date of death as would have lapsed had the Participant not died. The proration shall be based upon the number of days accrued prior to the
Participant’s date of death. 

	22.	 PURCHASE FOR INVESTMENT. 

Unless the offering and sale of the Shares to be issued upon the particular exercise or acceptance of a Stock Right shall have been effectively
registered under the Securities Act, the Company shall be under no obligation to issue the Shares covered by such exercise unless and until the following conditions have been fulfilled: 

(a) The person who exercises or accepts such Stock Right shall warrant to the Company, prior to the receipt of such Shares, that such person is
acquiring such Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound by the provisions of the
following legend (or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant: 

“The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws.” 

(b) At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued upon such
particular exercise or acceptance in compliance with the Securities Act without registration thereunder. 
  

	23.	 DISSOLUTION OR LIQUIDATION OF THE
COMPANY. 

 Upon the dissolution or liquidation of the Company, all Options granted under this Plan which as of
such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that if the rights of a Participant or a Participant’s Survivors have not otherwise terminated
and expired, the Participant or the Participant’s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to
acceptance as of the date immediately prior to such dissolution or liquidation. 
  

	24.	 ADJUSTMENTS. 

Upon the occurrence of any of the following events, a Participant’s rights with respect to any Stock Right granted to him or her hereunder
shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant’s Agreement: 
 (a) Stock
Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common
Stock, or (ii) additional shares or new or different shares or other securities of the Company or other non- cash assets are distributed with respect to such shares of Common Stock, the number of shares of Common Stock deliverable upon the
exercise of an Option or acceptance of a Stock Grant shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made including, in the exercise or purchase price per share, to reflect such events. The number
of Shares subject to the limitations in Paragraph 3(a) shall also be proportionately adjusted upon the occurrence of such events. 

 (b) Corporate Transactions. If the Company is to be consolidated with or acquired by
another entity in a merger, consolidation, or sale of all or substantially all of the Company’s assets other than a transaction to merely change the state of incorporation (a “Corporate Transaction”), the Administrator or the board of
directors of any entity assuming the obligations of the Company hereunder (the “Successor Board”), shall, as to outstanding Options, either (i) make appropriate provision for the continuation of such Options by substituting on an
equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or
(ii) upon written notice to the Participants, provide that such Options must be exercised (either (A) to the extent then exercisable or, (B) at the discretion of the Administrator, any such Options being made partially or fully
exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate; or (iii) terminate such Options in exchange for
payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would have been exercisable (either (A) to the extent then
exercisable or, (B) at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph) less the aggregate exercise price thereof. For purposes
of determining the payments to be made pursuant to Subclause (iii) above, in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair
value thereof as determined in good faith by the Board of Directors. 
 With respect to outstanding Stock Grants, the Administrator or the
Successor Board, shall make appropriate provision for the continuation of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants either the consideration payable with
respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator may provide
that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number
of shares of Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being
waived upon such Corporate Transaction). 
 In taking any of the actions permitted under this Paragraph 24(b), the Administrator shall not
be obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. 

(c) Recapitalization or Reorganization. In the event of a recapitalization or reorganization of the Company
other than a Corporate Transaction pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an Option or accepting a Stock Grant after the
recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such Option had been exercised or Stock Grant accepted
prior to such recapitalization or reorganization. 

 (d) [Intentionally Omitted]. 

(e) Modification of Options. Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph (a), (b) or (c) above
with respect to Options shall be made only after the Administrator determines whether such adjustments would constitute a “modification” of any ISOs (as that term is defined in Section 424(h) of the Code) or would cause any adverse
tax consequences for the holders of Options, including, but not limited to, pursuant to Section 409A of the Code. If the Administrator determines that such adjustments made with respect to Options would constitute a modification or other
adverse tax consequence, it may refrain from making such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of
such “modification” on his or her income tax treatment with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion of the ISO to violate the annual vesting
limitation contained in Section 422(d) of the Code, as described in Paragraph 6(b)(iv). 
  

	25.	 ISSUANCES OF SECURITIES. 

Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock
of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in
property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. 
  

	26.	 FRACTIONAL SHARES. 

No fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such
fractional shares equal to the Fair Market Value thereof. 
  

	27.	 CONVERSION OF ISOS INTO NON-QUALIFIED OPTIONS; TERMINATION OF ISOS. 

The Administrator, at the written request of any Participant, may in its discretion take such actions as may be necessary to convert such
Participant’s ISOs (or any portions thereof) that have not been exercised on the date of conversion into Non-Qualified Options at any time prior to the expiration of such ISOs, regardless of whether the
Participant is an Employee of the Company or an Affiliate at the time of such conversion. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting Non-Qualified Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant the
right to have such Participant’s ISOs converted into Non-Qualified Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator, with the
consent of the Participant, may also terminate any portion of any ISO that has not been exercised at the time of such conversion. 

	28.	 WITHHOLDING. 

In the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act (“F.I.C.A.”)
withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant’s salary, wages or other remuneration in connection with the exercise or acceptance of a Stock Right or in connection
with a Disqualifying Disposition (as defined in Paragraph 29) or upon the lapsing of any forfeiture provision or right of repurchase or for any other reason required by law, the Company may withhold from the Participant’s compensation, if any,
or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding arrangement, including
the use of shares of the Company’s Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be
determined in the manner set forth under the definition of Fair Market Value provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount
of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion may condition the exercise of an Option for less than the then Fair
Market Value on the Participant’s payment of such additional withholding. 
  

	29.	 NOTICE TO COMPANY OF DISQUALIFYING
DISPOSITION. 

 Each Employee who receives an ISO must agree to notify the Company in writing immediately after
the Employee makes a Disqualifying Disposition of any Shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and includes any disposition (including any sale or gift) of such
Shares before the later of (a) two years after the date the Employee was granted the ISO, or (b) one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section 424(c) of the Code.
If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. 
  

	30.	 TERMINATION OF THE PLAN. 

The Plan will terminate on December 12, 2028, the date which is ten years from the earlier of the date of its adoption by the Board of
Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board of Directors of the Company; provided, however, that any such earlier termination shall
not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore granted. 

	31.	 AMENDMENT OF THE PLAN AND
AGREEMENTS. 

 The Plan may be amended by the shareholders of the Company. The Plan may also be amended by the
Administrator, including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded
incentive stock options under Section 422 of the Code (including deferral of taxation upon exercise), and to the extent necessary to qualify the shares issuable upon exercise or acceptance of any outstanding Stock Rights granted, or Stock
Rights to be granted, under the Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities dealers. Any amendment approved by the Administrator which the Administrator determines is of
a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock Right
previously granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of
the Administrator, outstanding Agreements may be amended by the Administrator in a manner which is not adverse to the Participant. 
  

	32.	 EMPLOYMENT OR OTHER RELATIONSHIP. 

Nothing in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or
director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by the Company or any
Affiliate for any period of time. 
  

	33.	 GOVERNING LAW. 

This Plan shall be construed and enforced in accordance with the law of the State of Delaware. 

 AMENDMENT 

NO. 1 TO THE 
 AURA
BIOSCIENCES, INC. 
 2018 EQUITY INCENTIVE PLAN 

WHEREAS, Aura Biosciences, Inc. (the “Company”) maintains the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the
“Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the stockholders of the Company; 

WHEREAS, the Board desires to amend certain provisions of the Plan related to a sale of the Company; and 

WHEREAS, Section 31 of the Plan provides that the Board may amend the Plan at any time, subject to certain conditions set forth
therein. 
 NOW, THEREFORE: 

1. Section 1 of the Plan is hereby amended by adding the following definitions to the definitions set forth in Section 1 of the Plan: 

Initial Public Offering means the consummation of the first firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act covering the offer and sale by the Company of its equity securities, as a result of or following which the Shares shall be publicly held. 

Person shall mean any individual, corporation, partnership (limited or general), limited liability company, limited
liability partnership, association, trust, joint venture, unincorporated organization or any similar entity. 
 Sale
Event means the consummation of (i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (iii) a merger,
reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the surviving or resulting entity (or its
ultimate parent, if applicable), (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a Person or group of Persons, or (v) any other acquisition
of the business of the Company, as determined by the Board of Directors; provided, however, that the Company’s Initial Public Offering, any subsequent public offering or another capital raising event, or a merger effected solely to
change the Company’s domicile shall not constitute a “Sale Event.” 
 2. Section 23 of the Plan is hereby deleted in its
entirety and replaced with the following: 
 “Upon a Sale Event (solely as defined in section (i) of “Sale
Event”), all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that if the rights of a Participant
or a Participant’s Survivors have not otherwise terminated and expired, the Participant or the Participant’s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the
extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. 

 3. Section 24(b) and (c) of the Plan are hereby deleted in their entirety and replaced
with the following: 
 (b) Sale Events. In the event of a Sale Event (other than as defined in section (i) of
“Sale Event”), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the “Successor Board”), shall, as to outstanding Options, either (i) make appropriate provision for
the continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Sale Event or
securities of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that such Options must be exercised (either (A) to the extent then exercisable or, (B) at the discretion of the Administrator,
any such Options being made partially or fully exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate; or
(iii) terminate such Options in exchange for payment of an amount equal to the consideration payable upon consummation of such Sale Event to a holder of the number of shares of Common Stock into which such Option would have been exercisable
(either (A) to the extent then exercisable or, (B) at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph) less the aggregate exercise price thereof. For
purposes of determining the payments to be made pursuant to Subclause (iii) above, in the case of a Sale Event the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair
value thereof as determined in good faith by the Board of Directors. 
 With respect to outstanding Stock Grants, the
Administrator or the Successor Board, shall make appropriate provision for the continuation of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants either the
consideration payable with respect to the outstanding Shares of Common Stock in connection with the Sale Event or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Sale Event, the Administrator may
provide that, upon consummation of the Sale Event, each outstanding Stock Grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Sale Event to a holder of the number of shares of
Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon
such Sale Event). 
 In taking any of the actions permitted under this Paragraph 24(b), the Administrator shall not be
obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. 

 (c) Recapitalization or Reorganization. In the event of a
recapitalization or reorganization of the Company other than a Sale Event pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an
Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such
Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization. 
 4. Effective Date of
Amendment. This Amendment to the Plan shall become effective upon the date that it is approved by the Board. 
 5. Other
Provisions. Except as set forth above, all other provisions of the Plan shall remain unchanged. 
 IN WITNESS WHEREOF, this Amendment
No. 1 to the Plan has been adopted by the Board of Directors of the Company this 14th day of May 2021. 

 Option
No.                   
 AURA
BIOSCIENCES, INC. 
 Stock Option Grant Notice 

Stock Option Grant under the Company’s 2018 Equity Incentive Plan 

 

					
	1.	  	Name and Address of Participant:	  	 
		  		  	 
		  		  	 
			
	2.	  	Date of Option Grant:	  	 
			
	3.	  	Type of Grant [ISO or NQO]:	  	
		  	 	  	
			
	4.	  	Maximum Number of Shares for which this Option is exercisable:	  	 
			
	5.	  	Exercise (purchase) price per share:	  	 
			
	6.	  	Option Expiration Date:	  	 
			
	7.	  	Vesting Start Date:	  	 
			
	8.	  	Vesting Schedule:	  	

  

	(a)	 On the first anniversary of the Vesting Start Date (the “Initial Vesting Date”), 25% of the Shares
shall be vested; 

  

	(b)	 Following the Initial Vesting Date, an additional 6.25% of the Shares shall vest ratably in twelve consecutive
equal (rounded up or down to the next highest whole number of shares) quarterly installments, commencing on                , 201X and ending
on                , 201X; and 

  

	(c)	 [NOTE: include “double trigger” acceleration for employees only] [If the Participant’s
employment is terminated by the Company without Cause (as defined in the Company’s 2018 Equity Incentive Plan) within twelve (12) months after a Change of Control occurs, then all of the Participant’s unvested options will accelerate
and vest immediately. As used herein, “Change of Control” means the occurrence of any of the following events: 

  

	 	(i)	 The dissolution or liquidation of the Company; or 

 

	 	(ii)	 The sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated
person or entity (a “Person”); or 

	 	(iii)	 A merger, reorganization or consolidation involving the Company in which the shares of the Company’s
voting equity outstanding immediately prior to such transaction represent or are converted into or exchanged for securities of the surviving or resulting entity immediately upon completion of such transaction which represent less than fifty percent
(50%) of the outstanding voting power of such surviving or resulting entity; or 

  

	 	(iv)	 Any other acquisition of the business of the Company’s, as determined by the Board; provided, however,
that the Company’s initial public offering, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company’s domicile shall not constitute a “Change of Control.”

  

	 	(v)	 For clarity, “Change of Control” shall be interpreted, if applicable, in a manner, and limited to the
extent necessary, so that it will not cause adverse tax consequences under Section 409A of the Code.] 

 The vesting
is further subject to the other terms and conditions of this Agreement and the Company’s 2018 Equity Incentive Plan. 
 The Company and
the Participant acknowledge receipt of this Stock Option Grant Notice and agree to the terms of the Stock Option Agreement attached hereto and incorporated by reference herein, the Company’s 2018 Equity Incentive Plan and the terms of this
Option Grant as set forth above. 
  

			
	AURA BIOSCIENCES, INC.
	
	By:                                   
                                 
	Name:                                   
                            
	Title:                                   
                              
	
	
                          
                                         
                   
 Participant Name:

  
 2 

 AURA BIOSCIENCES, INC. 

STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS 

AGREEMENT made as of the date of grant set forth in the Stock Option Grant Notice by and between Aura Biosciences, Inc. (the
“Company”), a Delaware corporation, and the individual whose name appears on the Stock Option Grant Notice (the “Participant”). 

WHEREAS, the Company desires to grant to the Participant an Option to purchase shares of its common stock, $0.00001 par value per share (the
“Shares”), under and for the purposes set forth in the Company’s 2018 Equity Incentive Plan (the “Plan”); 

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the same meanings as in the
Plan; and 
 WHEREAS, the Company and the Participant each intend that the Option granted herein shall be of the type set forth in the Stock
Option Grant Notice. 
 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable
consideration, the parties hereto agree as follows: 
  

	 	1.	 GRANT OF OPTION. 

The Company hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth
in the Stock Option Grant Notice, on the terms and conditions and subject to all the limitations set forth herein, under United States securities and tax laws, and in the Plan, which is incorporated herein by reference. The Participant acknowledges
receipt of a copy of the Plan. 
  

	 	2.	 EXERCISE PRICE. 

The exercise price of the Shares covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice, subject to
adjustment, as provided in the Plan, in the event of a stock split, reverse stock split or other events affecting the holders of Shares after the date hereof (the “Exercise Price”). Payment shall be made in accordance with Paragraph 9 of
the Plan. 
  

	 	3.	 EXERCISABILITY OF OPTION. 

Subject to the terms and conditions set forth in this Agreement and the Plan, the Option granted hereby shall become vested and exercisable as
set forth in the Stock Option Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan. 

  
 3 

	 	4.	 TERM OF OPTION. 

This Option shall terminate on the Option Expiration Date as specified in the Stock Option Grant Notice and, if this Option is designated in
the Stock Option Grant Notice as an ISO and the Participant owns as of the date hereof more than 10% of the total combined voting power of all classes of capital stock of the Company or an Affiliate, such date may not be more than five years from
the date of this Agreement, but shall be subject to earlier termination as provided herein or in the Plan. 
 If the Participant ceases to
be an Employee, director or Consultant of the Company or of an Affiliate for any reason other than the death or Disability of the Participant, or termination of the Participant for Cause (the “Termination Date”), the Option to the extent
then vested and exercisable pursuant to Section 3 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be exercised within three months after the Termination Date, or on or prior to the Option
Expiration Date as specified in the Stock Option Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below. In such event, the unvested portion of the Option shall not be exercisable and shall expire and be
cancelled on the Termination Date. 
 If this Option is designated in the Stock Option Grant Notice as an ISO and the Participant ceases to
be an Employee of the Company or of an Affiliate but continues after termination of employment to provide service to the Company or an Affiliate as a director or Consultant, this Option shall continue to vest in accordance with Section 3 above
as if this Option had not terminated until the Participant is no longer providing services to the Company. In such case, this Option shall automatically convert and be deemed a Non-Qualified Option as of the
date that is three months from termination of the Participant’s employment and this Option shall continue on the same terms and conditions set forth herein until such Participant is no longer providing service to the Company or an Affiliate.

 Notwithstanding the foregoing, in the event of the Participant’s Disability or death within three months after the Termination Date,
the Participant or the Participant’s Survivors may exercise the Option within one year after the Termination Date, but in no event after the Option Expiration Date as specified in the Stock Option Grant Notice. 

In the event the Participant’s service is terminated by the Company or an Affiliate for Cause, the Participant’s right to exercise
any unexercised portion of this Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and this Option shall thereupon terminate. Notwithstanding anything herein to the
contrary, if subsequent to the Participant’s termination, but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant’s termination, the Participant engaged in conduct which
would constitute Cause, then the Participant shall immediately cease to have any right to exercise the Option and this Option shall thereupon terminate. 

In the event of the Disability of the Participant, as determined in accordance with the Plan, the Option shall be exercisable within one year
after the Participant’s termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable: 

 

	 	(a)	 to the extent that the Option has become exercisable but has not been exercised as of the date of the
Participant’s termination of service due to Disability; and 

  
 4 

	 	(b)	 in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of the Participant’s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days
accrued in the current vesting period prior to the date of the Participant’s termination of service due to Disability. 

In the event of the death of the Participant while an Employee, director or Consultant of the Company or of an Affiliate, the Option shall be
exercisable by the Participant’s Survivors within one year after the date of death of the Participant or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be
exercisable: 
  

	 	(x)	 to the extent that the Option has become exercisable but has not been exercised as of the date of death; and

  

	 	(y)	 in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant’s
date of death. 

  

	 	5.	 METHOD OF EXERCISING OPTION. 

Subject to the terms and conditions of this Agreement, the Option may be exercised by written notice to the Company or its designee, in
substantially the form of Exhibit A attached hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which the Option is being exercised and
shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in accordance with Paragraph 9 of the Plan. The
Company shall deliver such Shares as soon as practicable after the notice shall be received, provided, however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems
necessary under any applicable law (including, without limitation, state securities or “blue sky” laws). The Shares as to which the Option shall have been so exercised shall be registered in the Company’s share register in the name of
the person so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice exercising the Option, shall be registered in the Company’s share register in the name of the
Participant and another person jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall be exercised, pursuant to Section 4
hereof, by any person other than the Participant, such notice shall be accompanied by appropriate proof of the right of such person to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall
be fully paid and nonassessable. 

  
 5 

	 	6.	 PARTIAL EXERCISE. 

Exercise of this Option to the extent above stated may be made in part at any time and from time to time within the above limits, except that
no fractional share shall be issued pursuant to this Option. 
  

	 	7.	 NON-ASSIGNABILITY. 

The Option shall not be transferable by the Participant otherwise than by will or by the laws of descent and distribution. If this Option is a Non-Qualified Option then it may also be transferred pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except
as provided above in this paragraph, the Option shall be exercisable, during the Participant’s lifetime, only by the Participant (or, in the event of legal incapacity or incompetency, by the Participant’s guardian or representative) and
shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition
of the Option or of any rights granted hereunder contrary to the provisions of this Section 7, or the levy of any attachment or similar process upon the Option shall be null and void. 

 

	 	8.	 NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE. 

The Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the
Company’s share register in the name of the Participant. Except as is expressly provided in the Plan with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the
record date is prior to the date of such registration. 
  

	 	9.	 ADJUSTMENTS. 

The Plan contains provisions covering the treatment of Options in a number of contingencies such as stock splits and mergers. Provisions in the
Plan for adjustment with respect to stock subject to Options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. 

 

	 	10.	 TAXES. 

The Participant acknowledges and agrees that (i) any income or other taxes due from the Participant with respect to this Option or the
Shares issuable upon exercise of this Option shall be the Participant’s responsibility; (ii) the Participant was free to use professional advisors of his or her choice in connection with this Agreement, has received advice from his or her
professional advisors in connection with this Agreement, understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii) the Participant has not received and is not relying upon any advice,
representations or assurances made by or on behalf of the Company or any Affiliate or any Employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares or other matters

  
 6 

 
contemplated by this Agreement and (iv) neither the Administrator, the Company, its Affiliates, nor any of its officers or directors, shall be held liable for any applicable costs, taxes, or
penalties associated with the Option if, in fact, the Internal Revenue Service were to determine that the Option constitutes deferred compensation under Section 409A of the Code. 

If this Option is designated in the Stock Option Grant Notice as a Non-Qualified Option or if the
Option is an ISO and is converted into a Non-Qualified Option and such Non- Qualified Option is exercised, the Participant agrees that the Company may withhold from the Participant’s remuneration, if any,
the minimum statutory amount of federal, state and local withholding taxes attributable to such amount that is considered compensation includable in such person’s gross income. At the Company’s discretion, the amount required to be
withheld may be withheld in cash from such remuneration, or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option. The Participant further agrees that, if the Company does not withhold an amount from the
Participant’s remuneration sufficient to satisfy the Company’s income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld. 

 

	 	11.	 PURCHASE FOR INVESTMENT. 

Unless the offering and sale of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under
the Securities Act of 1933, as now in force or hereafter amended (the “1933 Act”), the Company shall be under no obligation to issue the Shares covered by such exercise unless the Company has determined that such exercise and issuance
would be exempt from the registration requirements of the 1933 Act and until the following conditions have been fulfilled: 
  

	 	(a)	 The person(s) who exercise the Option shall warrant to the Company, at the time of such exercise, that such
person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by
the provisions of the following legend which shall be endorsed upon any certificate(s) evidencing the Shares issued pursuant to such exercise: 

“The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws;” and 

(b) If the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular
exercise in compliance with the 1933 Act without registration thereunder. Without limiting the generality of the foregoing, the Company may delay issuance of the Shares until completion of any action or obtaining of any consent, which the Company
deems necessary under any applicable law (including without limitation state securities or “blue sky” laws). 

  
 7 

	 	12.	 RESTRICTIONS ON TRANSFER OF SHARES; JOINDER TO STOCKHOLDER AGREEMENTS. 

12.1 As a condition precedent to the exercise of the Option granted hereby, the grant of the Option or the delivery of certificates for Shares
issued upon exercise of the Option, the Participant must execute any and all agreements as may be requested by the Administrator, including, without limitation, a shareholders’ agreement, voting agreement, and right of first refusal and co-sale agreement. 
 12.2 The Shares acquired by the Participant pursuant to the exercise of the Option
granted hereby shall not be transferred by the Participant except as permitted herein. 
 12.3 It shall be a condition precedent to the
validity of any sale or other transfer of any Shares by the Participant that the following restrictions be complied with (except as otherwise provided in this Section 12): 

 

	 	(i)	 No Shares owned by the Participant may be sold, pledged or otherwise transferred (including by gift or devise)
to any person or entity, voluntarily, or by operation of law, except in accordance with the terms and conditions hereinafter set forth. 

  

	 	(ii)	 Before selling or otherwise transferring all or part of the Shares, the Participant shall give written notice
of such intention to the Company, which notice shall include the name of the proposed transferee, the proposed purchase price per share, the terms of payment of such purchase price and all other matters relating to such sale or transfer and shall be
accompanied by a copy of the binding written agreement of the proposed transferee to purchase the Shares of the Participant. Such notice shall constitute a binding offer by the Participant to sell to the Company such number of the Shares then held
by the Participant as are proposed to be sold in the notice at the monetary price per share designated in such notice, payable on the terms offered to the Participant by the proposed transferee (provided, however, that the Company shall not be
required to meet any non-monetary terms of the proposed transfer, including, without limitation, delivery of other securities in exchange for the Shares proposed to be sold). The Company shall give written
notice to the Participant as to whether such offer has been accepted in whole by the Company within 60 days after its receipt of written notice from the Participant. The Company may only accept such offer in whole and may not accept such offer in
part. Such acceptance notice shall fix a time, location and date for the Closing on such purchase (“Closing Date”) which shall not be less than ten nor more than sixty days after the giving of the acceptance notice, provided, however, if
any of the Shares to be sold pursuant to this Section 12.3 have been held by the Participant for less than six months, then the Closing Date may be extended by the Company until no more than ten days after such Shares have been held by the
Participant for six months if required under applicable accounting rules in effect at the time. The place 

  
 8 

	 	
for such Closing shall be at the Company’s principal office. At such Closing, the Participant shall accept payment as set forth herein and shall deliver to the Company in exchange therefor
certificates for the number of Shares stated in the notice accompanied by duly executed instruments of transfer. 

  

	 	(iii)	 If the Company shall fail to accept any such offer, the Participant shall be free to sell all, but not less
than all, of the Shares set forth in his or her notice to the designated transferee at the price and terms designated in the Participant’s notice, provided that (i) such sale is consummated within six months after the giving of notice by
the Participant to the Company as aforesaid, and (ii) the transferee first agrees in writing to be bound by the provisions of this Section 12 so that such transferee (and all subsequent transferees) shall thereafter only be permitted to
sell or transfer the Shares in accordance with the terms hereof. After the expiration of such six months, the provisions of this Section 12.3 shall again apply with respect to any proposed voluntary transfer of the Participant’s Shares.

  

	 	(iv)	 The restrictions on transfer contained in this Section 12.3 shall not apply to (a) transfers by the
Participant to his or her spouse or children or to a trust for the benefit of his or her spouse or children, (b) transfers by the Participant to his or her guardian or conservator, and (c) transfers by the Participant, in the event of his
or her death, to his or her executor(s) or administrator(s) or to trustee(s) under his or her will (collectively, “Permitted Transferees”); provided however, that in any such event the Shares so transferred in the hands of each such
Permitted Transferee shall remain subject to this Agreement, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. 

 

	 	(v)	 The provisions of this Section 12.3 may be waived by the Company. Any such waiver may be unconditional or
based upon such conditions as the Company may impose. 

 12.4 In the event that the Participant or his or her successor in
interest fails to deliver the Shares to be repurchased by the Company under this Agreement, the Company may elect (a) to establish a segregated account in the amount of the repurchase price, such account to be turned over to the Participant or
his or her successor in interest upon delivery of such Shares, and (b) immediately to take such action as is appropriate to transfer record title of such Shares from the Participant to the Company and to treat the Participant and such Shares in
all respects as if delivery of such Shares had been made as required by this Agreement. The Participant hereby irrevocably grants the Company a power of attorney which shall be coupled with an interest for the purpose of effectuating the preceding
sentence. 
 12.5 If the Company shall pay a stock dividend or declare a stock split on or with respect to any of its Common Stock, or
otherwise distribute securities of the Company to the holders of its Common Stock, the number of shares of stock or other securities of the Company issued with respect to the shares then subject to the restrictions contained in this Agreement shall
be added to the Shares subject to the Company’s rights to repurchase pursuant to this Agreement. If the Company shall distribute to its stockholders shares of stock of another corporation, the shares of stock of such other corporation,
distributed with respect to the Shares then subject to the restrictions contained in this Agreement, shall be added to the Shares subject to the Company’s rights to repurchase pursuant to this Agreement. 

  
 9 

 12.6 If the outstanding shares of Common Stock of the Company shall be subdivided into a
greater number of shares or combined into a smaller number of shares, or in the event of a reclassification of the outstanding shares of Common Stock of the Company, or if the Company shall be a party to a merger, consolidation or capital
reorganization, there shall be substituted for the Shares then subject to the restrictions contained in this Agreement such amount and kind of securities as are issued in such subdivision, combination, reclassification, merger, consolidation or
capital reorganization in respect of the Shares subject immediately prior thereto to the Company’s rights to repurchase pursuant to this Agreement. 

12.7 The Company shall not be required to transfer any Shares on its books which shall have been sold, assigned or otherwise transferred in
violation of this Agreement, or to treat as owner of such Shares, or to accord the right to vote as such owner or to pay dividends to, any person or organization to which any such Shares shall have been so sold, assigned or otherwise transferred, in
violation of this Agreement. 
 12.8 The provisions of Sections 12.1 and 12.3 shall terminate upon the effective date of the registration of
the Shares pursuant to the Securities Exchange Act of 1934. 
 12.9 The Participant agrees that in the event the Company proposes to offer
for sale to the public any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares,
then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such
period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with NASD Rule 2711 or similar rules thereto (such period,
the “Lock-Up Period”). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and
conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of
the Lock-Up Period. 
 12.10 In the event that the Initiating Holders (as defined below) approve a
Sale of the Company (as defined below) then the Participant hereby agrees with respect to the Shares and any other shares of Common Stock that the Participant holds and any other Company securities over which the Participant otherwise exercises
dispositive power (the “Drag Along”): 
  

	 	(i)	 in the event such transaction requires the approval of stockholders, (1) if the matter is to be brought to
a vote at a stockholder meeting, after receiving proper notice of any meeting of stockholders of the Company to vote on the approval of a Sale of the Company, to be present, in person or by proxy, as a holder of Shares, at all such meetings and be
counted for the purposes of determining the presence of a quorum at such meetings; and (2) to vote (in 

  
 10 

	 	
person, by proxy or by action by written consent, as applicable) all Shares in favor of such Sale of the Company and in opposition of any and all other proposals that could reasonably be expected
to delay or impair the ability of the Company to consummate such Sale of the Company; 

  

	 	(ii)	 to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time
with respect to such Sale of the Company; and 

  

	 	(iii)	 to execute and deliver all related documentation and take such other action in support of the Sale of the
Company as shall reasonably be requested by the Company. 

 As used herein, the following terms shall have the following
respective meanings: 
 “Initiating Holders” means Persons holding not less than 50.1% of the shares of Common
Stock of the Company then outstanding, determined on an as-converted basis (and including, for this purpose, any and all shares of Common Stock issued or issuable upon conversion of the Company’s
convertible preferred stock, but specifically excluding, for this purpose, any then outstanding options and warrants). 
 “Sale of the
Company” means: 
  

	 	(i)	 a merger or consolidation in which (A) the Company is a constituent party or (B) a subsidiary of the
Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the
Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by
voting power, of the capital stock of (1) the surviving or resulting corporation or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the
parent corporation of such surviving or resulting corporation (provided that, for the purpose of this clause (i) all shares of Common Stock issuable upon exercise of options or warrants outstanding immediately prior to such merger or
consolidation or upon conversion of convertible securities immediately prior to such merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such
merger or consolidation on the same terms as the actual outstanding shares of Common Stock are converted or exchanged); 

  

	 	(ii)	 any transaction or series of related transactions to which the Company is a party in which in excess of fifty
percent (50%) of the Company’s voting power is transferred such that the stockholders of the Company immediately prior to the transaction or series of related transactions do not own a majority of the voting power of the surviving or acquiring
entity following such transaction or series of transactions; other than any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or indebtedness of the
Company is cancelled or converted or a combination thereof; or 

  
 11 

	 	(iii)	 the sale, lease, transfer, exclusive license (other than an exclusive license that is approved by the Board of
Directors, or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or the sale or
disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale,
lease, transfer, exclusive license (other than an exclusive license that is approved by the Board of Directors or other disposition is to a wholly owned subsidiary of the Company. 

12.11 The Participant acknowledges and agrees that neither the Company, its shareholders nor its directors and officers, has any duty or
obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following a termination of the service of the Participant by the Company,
including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity. 

12.12 All certificates representing the Shares to be issued to the Participant pursuant to this Agreement shall have endorsed thereon a legend
substantially as follows: “The shares represented by this certificate are subject to restrictions set forth in a Stock Option Agreement dated as the date of the Stock Option Grant Notice between the Participant and the Company, a copy of which
Agreement is available for inspection at the offices of the Company or will be made available upon request.” 
  

	 	13.	 NO OBLIGATION TO MAINTAIN RELATIONSHIP. 

The Participant acknowledges that: (i) the Company is not by the Plan or this Option obligated to continue the Participant as an Employee,
director or Consultant of the Company or an Affiliate; (ii) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii) the grant of the Option is a
one-time benefit which does not create any contractual or other right to receive future grants of options, or benefits in lieu of options; (iv) all determinations with respect to any such future grants,
including, but not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or times when each option shall be exercisable, will be at the sole discretion of the Company;
(v) the Participant’s participation in the Plan is voluntary; (vi) the value of the Option is an extraordinary item of compensation which is outside the scope of the Participant’s employment or consulting contract, if any; and
(vii) the Option is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. 

  
 12 

	 	14.	 IF OPTION IS INTENDED TO BE AN ISO. 

If this Option is designated in the Stock Option Grant Notice as an ISO so that the Participant (or the Participant’s Survivors) may
qualify for the favorable tax treatment provided to holders of Options that meet the standards of Section 422 of the Code then any provision of this Agreement or the Plan which conflicts with the Code so that this Option would not be deemed an
ISO is null and void and any ambiguities shall be resolved so that the Option qualifies as an ISO. The Participant should consult with the Participant’s own tax advisors regarding the tax effects of the Option and the requirements necessary to
obtain favorable tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements. 

Notwithstanding the foregoing, to the extent that the Option is designated in the Stock Option Grant Notice as an ISO and is not deemed
to be an ISO pursuant to Section 422(d) of the Code because the aggregate Fair Market Value (determined as of the Date of Option Grant) of any of the Shares with respect to which this ISO is granted becomes exercisable for the first time during
any calendar year in excess of $100,000, the portion of the Option representing such excess value shall be treated as a Non-Qualified Option and the Participant shall be deemed to have taxable income measured
by the difference between the then Fair Market Value of the Shares received upon exercise and the price paid for such Shares pursuant to this Agreement. 

Neither the Company nor any Affiliate shall have any liability to the Participant, or any other party, if the Option (or any part thereof)
that is intended to be an ISO is not an ISO or for any action taken by the Administrator, including without limitation the conversion of an ISO to a Non-Qualified Option. 

 

	 	15.	 NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION OF AN ISO. 

If this Option is designated in the Stock Option Grant Notice as an ISO then the Participant agrees to notify the Company in writing
immediately after the Participant makes a Disqualifying Disposition of any of the Shares acquired pursuant to the exercise of the ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and includes any disposition (including
any sale) of such Shares before the later of (a) two years after the date the Participant was granted the ISO or (b) one year after the date the Participant acquired Shares by exercising the ISO, except as otherwise provided in
Section 424(c) of the Code. If the Participant has died before the Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. 

 

	 	16.	 NOTICES. 

Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile,
registered or certified mail, return receipt requested, addressed as follows: 
  

			
	If to the Company:	  	 Aura Biosciences
 85 Bolton Street

		  	Cambridge, MA 02140
		  	Attention: Chief Executive Officer

  
 13 

 If to the Participant at the address set forth on the Stock Option Grant Notice or to such other address or
addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following delivery to a recognized courier service or three business days
following mailing by registered or certified mail. 
  

	 	17.	 GOVERNING LAW. 

This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflict
of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Massachusetts and agree that such litigation shall be conducted in the
state and federal courts sitting in Massachusetts. 
  

	 	18.	 BENEFIT OF AGREEMENT. 

Subject to the provisions of the Plan and the other provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the
heirs, executors, administrators, successors and assigns of the parties hereto. 
  

	 	19.	 ENTIRE AGREEMENT. 

This Agreement, together with the Plan, embodies the entire agreement and understanding between the parties hereto with respect to the subject
matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be
used to interpret, change or restrict, the express terms and provisions of this Agreement, provided, however, in any event, this Agreement shall be subject to and governed by the Plan. 

 

	 	20.	 MODIFICATIONS AND AMENDMENTS. 

The terms and provisions of this Agreement may be modified or amended as provided in the Plan. 

 

	 	21.	 WAIVERS AND CONSENTS. 

Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement,
whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 

  
 14 

	 	22.	 DATA PRIVACY. 

By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any
Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options
and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 15 

 Exhibit A 

NOTICE OF EXERCISE OF STOCK OPTION 

[Form for Unregistered Shares] 

To:    Aura Biosciences, Inc. 
 Ladies and
Gentlemen: 
 I hereby exercise my Stock Option to
purchase                shares (the “Shares”) of the common stock, $0.00001 par value, of Aura Biosciences, Inc. (the “Company”), at the
exercise price of $            per share, pursuant to and subject to the terms of that certain Stock Option Agreement between the undersigned and the Company
dated                , 201_. 
 I am aware that the
Shares have not been registered under the Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws. I understand that the reliance by the Company on exemptions under the 1933 Act is predicated in part upon the
truth and accuracy of the statements by me in this Notice of Exercise. 
 I hereby represent and warrant that (1) I have been furnished
with all information which I deem necessary to evaluate the merits and risks of the purchase of the Shares; (2) I have had the opportunity to ask questions concerning the Shares and the Company and all questions posed have been answered to my
satisfaction; (3) I have been given the opportunity to obtain any additional information I deem necessary to verify the accuracy of any information obtained concerning the Shares and the Company; and (4) I have such knowledge and
experience in financial and business matters that I am able to evaluate the merits and risks of purchasing the Shares and to make an informed investment decision relating thereto. 

I hereby represent and warrant that I am purchasing the Shares for my own personal account for investment and not with a view to the sale or
distribution of all or any part of the Shares. 
 I understand that because the Shares have not been registered under the 1933 Act, I must
continue to bear the economic risk of the investment for an indefinite time and the Shares cannot be sold unless the Shares are subsequently registered under applicable federal and state securities laws or an exemption from such registration
requirements is available. 
 I agree that I will in no event sell or distribute or otherwise dispose of all or any part of the Shares
unless (1) there is an effective registration statement under the 1933 Act and applicable state securities laws covering any such transaction involving the Shares or (2) the Company receives an opinion of my legal counsel (concurred in by
legal counsel for the Company) stating that such transaction is exempt from registration or the Company otherwise satisfies itself that such transaction is exempt from registration. 

 

  
 Exhibit A-1 

 I consent to the placing of a legend on my certificate for the Shares stating that the
Shares have not been registered and setting forth the restriction on transfer contemplated hereby and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the Shares until the Shares may be legally
resold or distributed without restriction. 
 I understand that at the present time Rule 144 of the Securities and Exchange Commission (the
“SEC”) may not be relied on for the resale or distribution of the Shares by me. I understand that the Company has no obligation to me to register the sale of the Shares with the SEC and has not represented to me that it will register the
sale of the Shares. 
 I understand the terms and restrictions on the right to dispose of the Shares set forth in the 2019 Equity Incentive
Plan and the Stock Option Agreement, both of which I have carefully reviewed. I consent to the placing of a legend on my certificate for the Shares referring to such restriction and the placing of stop transfer orders until the Shares may be
transferred in accordance with the terms of such restrictions. 
 I have considered the Federal, state and local income tax implications of
the exercise of my Option and the purchase and subsequent sale of the Shares. 
 I am paying the option exercise price for the Shares as
follows: 
  

                       
                                         
                                         
                    
 Please issue the
Shares (check one): 
 ☐ to me; or 

☐ to me
and                                , as joint tenants with right of survivorship

 and mail the certificate to me at the following address: 
  

                          
                                         
      

                          
                                         
      

                          
                                         
      

  
 Exhibit A-2 

 My mailing address for shareholder communications, if different from the address listed
above is: 
  

                          
                                   

                          
                                   

                          
                                   

 

	
	Very truly yours,
	
	 
	Participant (signature)
	
	 
	Print Name
	
	 
	Date
	
	 
	Social Security Number

 Exhibit A-3 

 Exhibit B 

NOTICE OF EXERCISE OF STOCK OPTION 

[Form for Shares Registered in the United States] 

To:    Aura Biosciences, Inc. 
 IMPORTANT
NOTICE: This form of Notice of Exercise may only be used at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of the Shares for which this exercise is being made is
registered and such Registration Statement remains effective. 
 Ladies and Gentlemen: 

I hereby exercise my Stock Option to
purchase                shares (the “Shares”) of the common stock, $0.00001 par value, of Aura Biosciences, Inc. (the “Company”), at the
exercise price of $                per share, pursuant to and subject to the terms of that Stock Option Grant Notice
dated                         , 201_. 

I understand the nature of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have
consulted with competent tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and the purchase and subsequent sale of the Shares. 

I am paying the option exercise price for the Shares as follows: 
  

                       
                                         
                                         

Please issue the Shares (check one): 

☐ to me; or 
 ☐ to
me
and                                        
                                , as joint tenants with right of survivorship, 

at the following address: 

                          
                                         
                                    

                          
                                         
                                    

                          
                                         
                                    

Exhibit B-1 

 My mailing address for shareholder communications, if different from the address listed
above, is: 
  

                          
                                         
                                    

                          
                                         
                                    

                          
                                         
                                    

	
	Very truly yours,
	
	 
	        Participant (signature)
	
	 
	        Print Name
	
	 
	        Date
	
	 
	        Social Security Number

 Exhibit B-2 

 RESTRICTED STOCK AGREEMENT 

AURA BIOSCIENCES, INC. 

AGREEMENT made as of the            day
of            , 20     (the “Grant Date”), between AURA BIOSCIENCES, INC. (the “Company”), a Delaware corporation, and
             (the “Participant”). 
 WHEREAS, the
Company has adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the “Plan”) to promote the interests of the Company by providing an incentive for Employees, directors and Consultants of the Company or its Affiliates; 

WHEREAS, pursuant to the provisions of the Plan, the Company desires to offer to the Participant shares of the Company’s common stock,
$0.00001 par value per share (“Common Stock”), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; 

WHEREAS, the Participant wishes to accept said offer; and 

WHEREAS, the parties hereto understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the
Plan. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Terms of
Grant. The Participant hereby accepts the offer of the Company to issue to the Participant, in accordance with the terms of the Plan and this Agreement,
                     (            ) Shares of the Company’s
Common Stock (such shares, subject to adjustment pursuant to Section 24 of the Plan and Subsection 2.1(f) hereof, the “Granted Shares”) at a per share purchase price of $0.00001 (the “Purchase Price”), or an aggregate of $
receipt of which is hereby acknowledged by the Company. 
 2.1. Lapsing Forfeiture Right. 

(a) Lapsing Forfeiture Right. Except as set forth in Subsections 2.1(b), [(f)] or (g) hereof, in the event that for any reason the
Participant is no longer an Employee, director or Consultant of the Company or an Affiliate (the “Termination”) prior to            , 20    , the
Participant (or the Participant’s Survivor) shall, on the date of Termination, immediately forfeit to the Company (or its designee) all of the Granted Shares which have not yet vested in accordance with the schedule set forth below (the
“Lapsing Forfeiture Right”). 
 The Company’s Lapsing Forfeiture Right is as follows: 

On the first anniversary of the Vesting Start Date, 25% of the Shares shall be vested; and 

  
 1 

 If the Participant’s Termination is on or
after            , 20    , but prior to             , 20    ,
then 6.25% of Granted Shares shall vest ratably in twelve consecutive equal (rounded up or down to the next highest whole number of shares) quarterly installments over the next quarters, commencing on
            , 20         and ending on________, 20___. 

(b) Effect of Termination for Disability or upon Death. The following rules apply to the Company’s Lapsing Forfeiture Right if the
Participant’s Termination is by reason of Disability or death: to the extent the Company’s Lapsing Forfeiture Right has not lapsed as of the date of Termination due to Disability or death, as the case may be, the Participant shall forfeit
to the Company any or all of the Granted Shares subject to such Lapsing Forfeiture Right; provided, however, that the Company’s Lapsing Forfeiture Right shall be deemed to have lapsed to the extent of a pro rata portion of the Granted Shares
through the date of Termination due to Disability or death, as would have lapsed had the Participant not been terminated due to Disability or death, as the case may be. The proration shall be based upon the number of days accrued in such current
vesting period prior to the Participant’s date of Termination due to Disability or death, as the case may be. In the case of death all Granted Shares which are no longer subject to the Company’s Lapsing Forfeiture Right shall be issued to
the Participant’s Survivor. 
 (c) Escrow. The Granted Shares issued to the Participant hereunder which from time to time are
subject to the Lapsing Forfeiture Right shall be held in escrow by the Company as provided in this Subsection 2.1(c). Promptly following receipt by the Company of a written request from the Participant, the Company shall release from escrow and
deliver to the Participant the Granted Shares, if any, as to which the Company’s Lapsing Forfeiture Right has lapsed. In the event of forfeiture to the Company of Granted Shares subject to the Lapsing Forfeiture Right, the Company shall release
from escrow and cancel the number of Granted Shares so forfeited. Any securities distributed in respect of the Granted Shares held in escrow, including, without limitation, shares issued as a result of stock splits, stock dividends or other
recapitalizations (“Retained Distributions”) also be held in escrow in the same manner as the Granted Shares and all Retained Distributions shall be forfeited to the Company or released from escrow and delivered to the
Participant, as the case may be, at such time and in such manner as the Granted Shares to which such Retained Distributions so relate. 

(d) Prohibition on Transfer. The Participant recognizes and agrees that all Granted Shares and Retained Distributions which are subject
to the Lapsing Forfeiture Right may not be sold, transferred, assigned, hypothecated, pledged, encumbered or otherwise disposed of, whether voluntarily or by operation of law, other than to the Company (or its designee). However, the Participant,
with the approval of the Administrator, may transfer the Granted Shares and Retained Distributions for no consideration to or for the benefit of the Participant’s Immediate Family (including, without limitation, to a trust for the benefit of
the Participant’s Immediate Family or to a partnership or limited liability company for one or more members of the Participant’s Immediate Family), subject to such limits as the Administrator may establish, and the transferee shall remain
subject to all the terms and conditions applicable to this Agreement prior to such transfer and each 

  
 2 

 
such transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. The term “Immediate Family” shall mean the Participant’s spouse,
former spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers, nieces and nephews and grandchildren (and, for this purpose, shall also include the Participant. The Company shall not be required to transfer any Granted
Shares or Retained Distributions on its books which shall have been sold, assigned or otherwise transferred in violation of this Subsection 2.1(d), or to treat as the owner of such Granted Shares or Retained Distributions, or to accord the right to
vote as such owner or to pay dividends to, any person or organization to which any such Granted Shares or Retained Distributions shall have been so sold, assigned or otherwise transferred, in violation of this Subsection 2.1(d). 

(e) Failure to Deliver Granted Shares to be Forfeited. In the event that the Granted Shares to be forfeited to the Company under this
Agreement are not in the Company’s possession pursuant to Subsection 2.1(e) above or otherwise and the Participant or the Participant’s Survivor fails to deliver such Granted Shares to the Company (or its designee), the Company may
immediately take such action as is appropriate to transfer record title of such Granted Shares from the Participant to the Company (or its designee) and to treat the Participant and such Granted Shares in all respects as if delivery of such Granted
Shares had been made as required by this Agreement. The Participant hereby irrevocably grants the Company a power of attorney which shall be coupled with an interest for the purpose of effectuating the preceding sentence. 

(f) [Change of Control. Upon the closing of a Change in Control (as defined below) of the Company, the vesting schedule of the Granted
Shares shall be accelerated in full and the Company’s Lapsing Forfeiture Right shall have lapsed as to all Granted Shares upon the closing of such Change of Control.] 

(g) Adjustments. The Plan contains provisions covering the treatment of Shares in a number of contingencies such as stock splits and
mergers. Provisions in the Plan for adjustment with respect to the Granted Shares and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

 (h) [Certain Definition. As used herein, a “Change of Control” means the occurrence of any of the following
events: 
  

	 	1.	 Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the
“Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the
Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions which the Board of Directors does not approve; or 

  

	 	2.	 (A) A merger or consolidation of the Company whether or not approved by the Board of Directors, other than a
merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities 

  
 3 

	 	
of the surviving entity or the parent of such entity) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such
corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the sale or disposition by the Company of all or substantially all of the Company’s assets in a transaction requiring stockholder approval;
or 

  

	 	3.	 A change in the composition of the Board of Directors, as a result of which less than a majority of the
directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are directors of the Company as of January 1, 2019, or (B) are elected, or nominated for election, to the Board of Directors with
the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating
to the election of directors to the Company). 

  

	 	4.	 For clarity, “Change of Control” shall be interpreted, if applicable, in a manner, and limited to the
extent necessary, so that it will not cause adverse tax consequences under Section 409A of the Code.] 

 2.2
General Restrictions on Transfer of Granted Shares. 
 (a) Limitations on Transfer. In addition to the restrictions set forth
above in Section 2.1, the Granted Shares issued to the Participant hereunder and no longer subject to the Lapsing Forfeiture Right described in Section 2.1 herein (the “Vested Shares”) shall not be transferred by the Participant
except as permitted herein, shall be subject to the provisions of Sections 2.1(d), (e) and (f) above and shall be subject to the repurchase rights described in this Section 2.2. 

(b) Right to Repurchase following Termination of Service. In the event of the Participant’s Termination for any reason, including
due to death or Disability, then the Company shall have the option to repurchase the Vested Shares not previously forfeited to the Company in accordance with the provisions of Section 2.1 of this Agreement as follows: 

(i) The Company’s option to repurchase the Vested Shares in the event of Termination under this Section 2.2(b) shall
be valid for a period of one year commencing with the date of such Termination. 
 (ii) In the event the Company shall be
entitled to and shall elect to exercise its option to repurchase the Vested Shares under this Section 2.2(b), the Company shall notify the Participant, or in case of death, his or her Survivor, in writing of its intent to repurchase the Vested
Shares. Such written notice may be mailed by the Company up to and including the last day of the time period provided for in Section 2.2(b)(i) for exercise of the Company’s option to repurchase. 

  
 4 

 (iii) The written notice to the Participant shall specify the address at,
and the time and date on, which payment of the Repurchase Price (as hereinafter defined) is to be made (the “Post-Termination Repurchase Closing”). The date specified shall not be less than ten days nor more than 60 days from the date of
the mailing of the notice, and the Participant or the Participant’s Survivor with respect to the Vested Shares shall have no further rights as the owner thereof from and after the date specified in the notice. At the Post-Termination Repurchase
Closing, the Repurchase Price shall be delivered to the Participant or the Participant’s Survivor and the Vested Shares being purchased, duly endorsed for transfer, shall, to the extent that they are not then in the possession of the Company,
be delivered to the Company by the Participant or the Participant’s Survivor. 
 (iv) The price paid per share for any
Vested Shares repurchased hereunder (the “Repurchase Price”) shall equal the Fair Market Value of such Vested Shares determined in accordance with the Plan as of the date of Termination, provided, however, in the event of a Termination for
Cause, the Repurchase Price of the Vested Shares to be repurchased by the Company upon exercise of its option under this Section 2.2(b) shall be equal to $0.00001 per share. 

(c) Right to Repurchase on Proposed Transfer. It shall be a condition precedent to the validity of any sale or other transfer of any
Vested Shares by the Participant that the following restrictions be complied with (except as hereinafter otherwise provided): 

(i) No Vested Shares owned by the Participant may be sold, pledged or otherwise transferred (including by gift or devise) to
any person or entity, voluntarily, or by operation of law, except in accordance with the terms and conditions hereinafter set forth. 

(ii) Before selling or otherwise transferring all or part of the Vested Shares, the Participant shall give written notice of
such intention to the Company which notice shall include the name of the proposed transferee, the proposed purchase price per share, the terms of payment of such purchase price and all other matters relating to such sale or transfer and shall be
accompanied by a copy of the binding written agreement of the proposed transferee to purchase the Vested Shares of the Participant. Such notice shall constitute a binding offer by the Participant to sell to the Company such number of the Vested
Shares then held by the Participant as are proposed to be sold in the notice at the monetary price per share designated in such notice, payable on the terms offered to the Participant by the proposed transferee (provided, however, that the Company
shall not be required to meet any non-monetary terms of the proposed transfer, including, without limitation, delivery of other securities in exchange for the Vested Shares proposed to be sold). The Company
shall give written notice to the Participant as to whether such offer has been accepted in whole by the Company within 60 days after its receipt of written notice from the Participant. The Company may only accept such offer in whole and may not
accept such offer in part. Such acceptance notice shall fix a time, location and date for the closing on such purchase (the “Transfer Repurchase Closing”) which shall not be less than ten nor more than 60 days after the giving of the
acceptance notice, provided, however, if any of the Vested Shares to be sold pursuant to this Section 2.2(c) have been held by the Participant for less than six months, then the Transfer Repurchase Closing may be extended by the Company
until no more than ten days after such Vested Shares have been 

  
 5 

 
held by the Participant for six months. At the Transfer Repurchase Closing, the Participant shall accept payment as set forth herein and shall deliver to the Company in exchange therefor
the Vested Shares being repurchased, duly endorsed for transfer, to the extent that they are not then in the possession of the Company. 

(iii) If the Company shall fail to accept any such offer, the Participant shall be free to sell all, but not less than all, of
the Vested Shares set forth in his or her notice to the designated transferee at the price and terms designated in the Participant’s notice, provided that (a) such sale is consummated within six months after the giving of notice by the
Participant to the Company as aforesaid, and (b) the transferee first agrees in writing to be bound by the provisions of this Section 2.2(c) so that he or she (and all subsequent transferees) shall thereafter only be permitted to sell or
transfer the Vested Shares in accordance with the terms hereof. After the expiration of such six months, the provisions of this Section 2.2(c) shall again apply with respect to any proposed voluntary transfer of the Vested Shares. 

(iv) The provisions of this Section 2.2(c) may be waived by the Company. Any such waiver may be unconditional or based
upon such conditions as the Company may impose. 
 (v) The restrictions on transfer contained in this Section 2.2(c)
shall not apply to (a) transfers by the Participant to his or her spouse or children or to a trust for the benefit of his or her spouse or children, (b) transfers by the Participant to his or her guardian or conservator, or
(c) transfers by the Participant, in the event of his or her death, to his or her executor(s) or administrator(s) or to trustee(s) under his or her will (collectively, “Permitted Transferees”); provided however, that in any such event
the Vested Shares so transferred in the hands of each such Permitted Transferee shall remain subject to this Agreement, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such
transfer. 
 (d) The provisions of Section 2.2(a) through (c) shall terminate upon the effective date of the registration of the
Shares pursuant to the Exchange Act consummation of a public offering of any of the Company’s securities pursuant to a registration statement filed with the Securities and Exchange Commission pursuant to the Securities Act. 

(e) The Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such
Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares, then it will promptly sign such agreement and will not
transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such period as is determined by the Company and the
underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with NASD Marketplace Rule 2711 or similar rules thereto (such period, the
“Lock-Up Period”). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and
conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of
the Lock-Up Period. 

  
 6 

 (f) The Participant acknowledges and agrees that neither the Company, its shareholders nor
its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following the Participant’s
Termination, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity. 

3. Purchase for Investment; Securities Law Compliance. The Participant hereby represents and warrants that he or she is acquiring the
Granted Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Granted Shares. The Participant specifically acknowledges and agrees that any sales of Granted Shares
shall be made in accordance with the requirements of the Securities Act, in a transaction as to which the Company shall have received an opinion of counsel satisfactory to it confirming such compliance. The Participant shall be bound by the
provisions of the following legend which shall be endorsed upon the certificate(s) evidencing the Granted Shares: 
 “THE SHARES
REPRESENTED BY THIS CERTIFICATE HAVE BEEN TAKEN FOR INVESTMENT AND THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT TO SUCH SHARES SHALL BE EFFECTIVE
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS THEN AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE
WITH ALL APPLICABLE STATE SECURITIES LAWS.” 
 4. Legend. In addition to any legend required pursuant to the Plan, all
certificates representing the Granted Shares issued to the Participant pursuant to this Agreement shall have endorsed thereon a legend substantially as follows: 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS SET FORTH IN A RESTRICTED STOCK AGREEMENT DATED AS
OF                    , 20     WITH THIS COMPANY, A COPY OF WHICH AGREEMENT IS AVAILABLE FOR INSPECTION AT THE
OFFICES OF THE COMPANY OR WILL BE MADE AVAILABLE UPON REQUEST.” 
 5. Rights as a Stockholder. The Participant shall have all
the rights of a stockholder with respect to the Granted Shares, including voting and dividend rights, subject to the transfer and other restrictions set forth herein. 

6. Incorporation of the Plan. The Participant specifically understands and agrees that the Granted Shares issued under the Plan are
being sold to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has read and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference.

  
 7 

 7. Tax Liability of the Participant and Payment of Taxes. The Participant
acknowledges and agrees that any income or other taxes due from the Participant with respect to the Granted Shares issued pursuant to this Agreement, including, without limitation, the Lapsing Forfeiture Right, shall be the Participant’s
responsibility. Without limiting the foregoing, the Participant agrees that, to the extent that the lapsing of restrictions on disposition of any of the Granted Shares or the declaration of dividends on any such shares before the lapse of such
restrictions on disposition results in the Participant’s being deemed to be in receipt of earned income under the provisions of the Code, the Company shall be entitled to immediate payment from the Participant of the amount of any tax required
to be withheld by the Company. 
 Upon execution of this Agreement, the Participant may file an election under Section 83 of the Code
in substantially the form attached as Exhibit A. The Participant acknowledges that if he or she does not file such an election, as the Granted Shares are released from the Lapsing Forfeiture Right in accordance with Section 2.1, the
Participant will have income for tax purposes equal to the Fair Market Value of the Granted Shares at such date, less the price paid for the Granted Shares by the Participant. The Participant has been given the opportunity to obtain the advice of
his or her tax advisors with respect to the tax consequences of the purchase of the Granted Shares and the provisions of this Agreement. 

If the Participant has not filed an election under Section 83 of the Code, the Participant shall be required to deposit with the Company
an amount of cash equal to the amount determined by the Company to be required with respect to the statutory minimum of the Participant’s estimated total federal, state and local tax obligations associated with the termination of the Lapsing
Forfeiture Right with respect to the Granted Shares. 
 8. Equitable Relief. The Participant specifically acknowledges and agrees
that in the event of a breach or threatened breach of the provisions of this Agreement or the Plan, including the attempted transfer of the Granted Shares by the Participant in violation of this Agreement, monetary damages may not be adequate to
compensate the Company, and, therefore, in the event of such a breach or threatened breach, in addition to any right to damages, the Company shall be entitled to equitable relief in any court having competent jurisdiction. Nothing herein shall be
construed as prohibiting the Company from pursuing any other remedies available to it for any such breach or threatened breach. 
 9. No
Obligation to Maintain Relationship. The Participant acknowledges that: (i) the Company is not by the Plan or this Agreement obligated to continue the Participant as an Employee, director or Consultant of the Company or an Affiliate;
(ii) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii) the grant of the Granted Shares is a one-time benefit which does not create any
contractual or other right to receive future grants of Shares, or benefits in lieu of Shares; (iv) all determinations with respect to any such future grants, including, but not limited to, the times when Shares shall be granted, the number

  
 8 

 
of Shares to be granted, the purchase price, and the time or times when each Share shall be free from a lapsing repurchase or forfeiture right, will be at the sole discretion of the Company;
(v) the Participant’s participation in the Plan is voluntary; (vi) the value of the Granted Shares is an extraordinary item of compensation which is outside the scope of the Participant’s employment contract, if any; and
(vii) the Granted Shares are not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar
payments. 
 10. Notices. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized
courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows: 
 If to the Company: 

Aura Biosciences, Inc. 
 85 Bolton
Street 
 Cambridge, MA 02140 

Attention: Chief Executive Officer 

If to the Participant: 

                       
              

                       
              

                       
              
 or to such other address or addresses of which notice in the same
manner has previously been given. Any such notice shall be deemed to have been given on the earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by
registered or certified mail. 
 11. Benefit of Agreement. Subject to the provisions of the Plan and the other provisions hereof,
this Agreement shall be for the benefit of and shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto. 

12. Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving
effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in Massachusetts and agree that such
litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the First District. 
 13.
Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and
enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby. 

  
 9 

 14. Entire Agreement. This Agreement, together with the Plan, constitutes the entire
agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement provided, however, in any event, this Agreement shall be subject to and
governed by the Plan. 
 15. Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be
modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the
benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall
be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 

16. Consent of Spouse/Domestic Partner. If the Participant has a spouse or a domestic partner as of the date of this Agreement, the
Participant’s spouse or domestic partner shall execute a Consent of Spouse/Domestic Partner in the form of Exhibit B hereto, effective as of the date hereof. Such consent shall not be deemed to confer or convey to the spouse or domestic
partner any rights in the Granted Shares that do not otherwise exist by operation of law or the agreement of the parties. If the Participant subsequent to the date hereof, marries, remarries or applies to the Company for domestic partner benefits,
the Participant shall, not later than 60 days thereafter, obtain his or her new spouse’s/domestic partner’s acknowledgement of and consent to the existence and binding effect of all restrictions contained in this Agreement by having such
spouse/domestic partner execute and deliver a Consent of Spouse/Domestic Partner in the form of Exhibit B. 
 17.
Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 
 18. Data Privacy. By entering into this Agreement, the Participant: (i) authorizes the Company and each
Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall
request in order to facilitate the grant of Shares and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

 [THE NEXT PAGE IS THE SIGNATURE PAGE] 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

			
	AURA BIOSCIENCES, INC.

 
			
		
	By:	 	 
	Name:
	Title:

  

			
	PARTICIPANT:
	
	 
	Print name:

  
 11 

 EXHIBIT A 

Election to Include Gross Income in Year 

of Transfer Pursuant to Section 83(b) 

of the Internal Revenue Code of 1986, as amended 

In accordance with Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”), the undersigned hereby elects to include in his
gross income as compensation for services the excess, if any, of the fair market value of the property (described below) at the time of transfer over the amount paid for such property. 

The following sets forth the information required in accordance with the Code and the regulations promulgated thereunder: 

 

	1.	 The name, address and social security number of the undersigned are: 

Name: 
 Address: 

Social Security No.:
                              

 

	2.	 The description of the property with respect to which the election is being made is as follows:

                    
(            ) shares (the “Shares”) of Common Stock, $0.00001 par value per share, of AURA BIOSCIENCES, INC., a Delaware corporation (the “Company”). 

 

	3.	 This election is made for the calendar year 20    , with respect to the transfer of
the property to the taxpayer on            , 20    . 

  

	4.	 Description of restrictions: The property is subject to the following restrictions: 

In the event the taxpayer’s service with the Company or an affiliate of the Company is terminated (the “Termination”), the
taxpayer shall forfeit the Shares as set forth below: 
 If the Termination takes place
after            , 20    , the number of Shares forfeited shall be          minus 6.25%
for each full quarter elapsed after            , 20__ that the taxpayer was employed by the Company or an affiliate of the Company or provided services as a consultant to or director
of the Company or an affiliate of the Company. 
  

	5.	 The fair market value at the time of transfer (determined without regard to any restrictions other than
restrictions which by their terms will never lapse) of the property with respect to which this election is being made was not more than $.0001 per Share. 

  

	6.	 The amount paid by taxpayer for said property was $.0001 per Share. 

 

	7.	 A copy of this statement has been furnished to the Company. 

  
 A- 

 Signed this        day
of            , 20    . 
  

			
	Print Name:

  
 A- 

 EXHIBIT B 

CONSENT OF SPOUSE/DOMESTIC PARTNER 

I,                       
                     , spouse or domestic partner of
                                        ,
acknowledge that I have read the RESTRICTED STOCK AGREEMENT dated as of                    , 20__ (the “Agreement”) to which this
Consent is attached as Exhibit B and that I know its contents. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Agreement. I am aware that by its provisions the Granted Shares granted to my
spouse/domestic partner pursuant to the Agreement are subject to a Lapsing Forfeiture Right in favor of Aura Biosciences, Inc. (the “Company”) and that, accordingly, I may be required to forfeit to the Company any or all of the Granted
Shares of which I may become possessed as a result of a gift from my spouse/domestic partner or a court decree and/or any property settlement in any domestic litigation. 

I hereby agree that my interest, if any, in the Granted Shares subject to the Agreement shall be irrevocably bound by the Agreement and
further understand and agree that any community property interest I may have in the Granted Shares shall be similarly bound by the Agreement. 

I agree to the Lapsing Forfeiture Right described in the Agreement and I hereby consent to the forfeiture of the Granted Shares to the Company
by my spouse/domestic partner or my spouse/domestic partner’s legal representative in accordance with the provisions of the Agreement. Further, as part of the consideration for the Agreement, I agree that at my death, if I have not disposed of
any interest of mine in the Granted Shares by an outright bequest of the Granted Shares to my spouse/domestic partner, then the Company shall have the same rights against my legal representative to exercise its rights to the Granted Shares with
respect to any interest of mine in the Granted Shares as it would have had pursuant to the Agreement if I had acquired the Granted Shares pursuant to a court decree in domestic litigation. 

I AM AWARE THAT THE LEGAL, FINANCIAL AND RELATED MATTERS CONTAINED IN THE AGREEMENT ARE COMPLEX AND THAT I AM FREE TO SEEK INDEPENDENT
PROFESSIONAL GUIDANCE OR COUNSEL WITH RESPECT TO THIS CONSENT. I HAVE EITHER SOUGHT SUCH GUIDANCE OR COUNSEL OR DETERMINED AFTER REVIEWING THE AGREEMENT CAREFULLY THAT I WILL WAIVE SUCH RIGHT. 

Dated as of the            day
of                            , 20    . 

 

			
	Print name:

  
 B-1EX-10.11

 Exhibit 10.11 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

THE NATIONAL INSTITUTES OF HEALTH 

PATENT LICENSE AGREEMENT - EXCLUSIVE 

COVER PAGE 
 For the NIH internal use
only: 
 License Number: L-164-2013/0 

License Application Number: A-098-2012 

Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

[***] 
 Licensee: 

Aura Biosciences, Inc. 85 Bolton Street Cambridge, MA 02140 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Additional Remarks: 
 Public
Benefit(s): The treatment, diagnosis and imaging of cancer tumors and metastases as well as their respective pre-cursor dysplasia states. 

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a
Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty
Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are: 
  

	 	1)	 The National Institutes of Health (“NIH”), an agency of the United States Public Health
Service within the Department of Health and Human Services (“HHS”); and 

  

	 	2)	 The person, corporation, or institution identified above or on the Signature Page, having offices at the
address indicated on the Signature Page, hereinafter referred to as the “Licensee”. 

 The NIH and the Licensee
agree as follows: 
  

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the NIH or the FDA investigators made
inventions that may have commercial applicability. 

  

	 	1.2	 By assignment of rights from NIH or FDA employees and other inventors, HHS, on behalf of
the Government, owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. HHS also owns any tangible embodiments of these inventions actually
reduced to practice by the NIH of the FDA. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 1 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	1.3	 The Secretary of HHS has delegated to the NIH the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The NIH desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation
or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.2	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.3	 “Commercial Development Plan” means the written commercialization plan attached as
Appendix E. 

  

	 	2.4	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.5	 “FDA” means the Food and Drug Administration. 

 

	 	2.6	 “First Commercial Sale” means the initial transfer by or on behalf of the Licensee
or its sublicensees of the Licensed Products or the initial practice of a Licensed Process by or on behalf of the Licensee or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the
purpose of determining Net Sales. 

  

	 	2.7	 “Government” means the Government of the United States of America.

  

	 	2.8	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.9	 “Licensed Patent Rights” shall mean: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): 

  

	 	(i)	 continuations-in-part of
2.9(a); 

  

	 	(ii)	 all divisions and continuations of these
continuations-in-part; 

  

	 	(iii)	 all patents issuing from these
continuations-in-part, divisions, and continuations; 

  

	 	(iv)	 priority patent application(s) of 2.9(a); and 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 2 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): all counterpart foreign and U.S. patent applications and patents to 2.9(a) and 2.9(b), including those listed in Appendix A; and 

  

	 	(d)	 Licensed Patent Rights shall not include 2.9(b) or 2.9(c) to the extent that they contain one or
more claims directed to new matter which is not the subject matter disclosed in 2.9(a). 

  

	 	2.10	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

 

	 	2.11	 “Licensed Products” means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  

	 	2.12	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.13	 “Net Sales” means [***] 

 

	 	2.14	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

	 	2.15	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The NIH hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. 

  

	 	3.2	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the NIH other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 Upon written approval, which shall include prior review of any sublicense agreement by the NIH and which
shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights. 

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the NIH
of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to this
Agreement. The Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 3 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the NIH, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to the NIH approval and contingent upon acceptance by the
sublicensee of the remaining provisions of this Agreement. 

  

	 	4.4	 The Licensee agrees to forward to the NIH a complete copy of each fully executed sublicense
agreement postmarked within [***] of the execution of the agreement. To the extent permitted by law, the NIH agrees to maintain each sublicense agreement in confidence. 

 

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

			
	 5.1
	 	 (a)   the NIH reserves on behalf of the Government an irrevocable,
nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or
international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. Prior to the First Commercial Sale, the Licensee agrees to provide the NIH with reasonable
quantities of the Licensed Products or materials made through the Licensed Processes for NIH research use; and

  

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(l)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights
or have the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial
information that is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First
Commercial Sale, the Licensee agrees to provide the NIH with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for NIH research use. 

 

	 	5.2	 The Licensee agrees that products used or sold in the United States embodying the Licensed Products
or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the NIH. 

 

	 	5.3	 The Licensee acknowledges that the NIH may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the NIH when acquiring
these rights is necessary in order to make a CRADA project feasible. The Licensee may request an opportunity to join as a party to the proposed CRADA. 

 

			
	 5.4
	 	 (a)   in addition to the reserved license of Paragraph 5.1, the NIH
reserves the right to grant Research Licenses directly or to require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether
conducted at an academic or corporate facility. In order to safeguard the Licensed Patent Rights, however, the NIH shall consult with the Licensee before granting to commercial entities a Research License or providing to
them research samples of materials made through the Licensed Processes; and

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 4 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(T)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to
use the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license
itself. The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; o 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the NIH a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the NIH a nonrefundable minimum annual royalty as set forth in
Appendix C. 

  

	 	6.3	 The Licensee agrees to pay the NIH earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the NIH benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the NIH sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the
Licensed Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses, or 

 

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of the Licensed Products by the Licensee to sublicensees or on sales made in other than
an arms-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction, based on sales of like quantity and quality products on or
about the time of this transaction. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 5 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	6.9	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIH prior to the effective date of this Agreement, the Licensee shall pay the NIH, as an additional royalty, within
sixty (60) days of the NIH’s submission of a statement and request for payment to the Licensee, an amount equivalent to [***] of these unreimbursed expenses previously paid by the NIH, [***] of the remaining balance due
ninety (90) days from the NIH’s initial submission of a statement and request for payment and the remaining balance (i.e. [***] due One Hundred Twenty (120) days from the NIH’s initial submission of a statement and
request for payment. 

  

	 	6.10	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIH on or after the effective date of this Agreement, the NIH, at its sole option, may require the Licensee;

 [***] 
  

	 	6.11	 The NIH agrees, upon written request, to provide the Licensee with summaries of patent
prosecution invoices for which the NIH has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the NIH related to patent prosecution costs shall be
treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction. 

  

	 	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon ninety (90) days written notice to the NIH and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after ninety (90) days of the effective
date of the written notice. 

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the NIH agrees to take responsibility for, but to
consult with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to
the Licensee. 

  

	 	7.2	 Upon the NIH’s written request, the Licensee shall assume the responsibility for the
preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the NIH.
In this event, the Licensee shall, subject to the prior approval of the NIH, select registered patent attorneys or patent agents to provide these services on behalf of the Licensee and the NIH. The NIH shall provide
appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The Licensee and its attorneys or agents shall consult with the NIH in all aspects
of the preparation, filing, prosecution and maintenance of patent applications and patents included within the Licensed Patent Rights and shall provide the NIH sufficient opportunity to comment on any document that the Licensee
intends to file or to cause to be filed with the relevant intellectual property or patent office. 

  

	 	7.3	 At any time, the NIH may provide the Licensee with written notice that the NIH wishes to
assume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. If the NIH elects to reassume these responsibilities, the Licensee
agrees to cooperate fully with the NIH, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and to provide the
NIH with complete copies of any and all documents or other materials that the NIH deems necessary to undertake such responsibilities. The Licensee shall be responsible for all costs associated with transferring patent
prosecution responsibilities to an attorney or agent of the NIH’s choice. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 6 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	7.4	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent Rights,
which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the NIH. These records shall be retained for at least five (5) years following a given
reporting period and shall be available during normal business hours for inspection, at the expense of the NIH, by an accountant or other designated auditor selected by the NIH for the sole purpose of verifying reports and royalty payments
hereunder. The accountant or auditor shall be required to execute s a reasonable confidentiality agreement with Licensee, and shall only disclose to the NIH information relating to the accuracy of reports and royalty payments made under this
Agreement. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then the Licensee shall reimburse the NIH for the reasonable cost of the inspection
at the time the Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within sixty (60) days of the date the NIH
provides to the Licensee notice of the payment due. 

  

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the NIH with the Commercial
Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated
by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	 The Licensee shall provide written annual reports on [***] for each of the Licensed Fields of Use
within [***]. These progress reports shall include, but not be limited to: [***]. The NIH also encourages these reports to include information on any of the Licensee’s public service activities that relate to the Licensed
Patent Rights. [***], the Licensee shall [***]. In the annual report, the Licensee may [***]. The Licensee agrees to provide any additional information reasonably required by the NIH to evaluate the
Licensee’s performance under this Agreement. The Licensee may amend the Benchmarks at any time upon written approval by the NIH. The NIH shall not unreasonably withhold approval of any request of the
Licensee to [***]. 

  

	 	9.3	 The Licensee shall report to the NIH the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

  

	 	9.4	 The Licensee shall submit to the NIH, within [***] after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf
of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned
royalties are due to the NIH for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee [***]. The royalty report shall also identify the site
of manufacture for the Licensed Product(s) sold in the United States. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 7 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	9.5	 The Licensee agrees to forward semi-annually to the NIH a copy of these reports received by the
Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the NIH by the Licensee for activities under the sublicense. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the NIH at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the NIH on any payment that is more than ninety (90) days overdue
at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the NIH of the overdue payment and additional royalties. The payment of any
additional royalties shall not prevent the NIH from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the NIH as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the NIH under the
Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

 

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include reasonable adherence to the Commercial Development Plan in Appendix E and performance of the
Benchmarks in Appendix D. The efforts of a sublicensee shall be considered the efforts of the Licensee. 

  

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to use reasonable commercial efforts to
make reasonable quantities of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products.

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 8 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	10.5	 The Licensee agrees to supply, to the Mailing Address for Agreement Notices indicated on the
Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for educational and display purposes only. 

 

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The NIH and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

 

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that the
NIH and appropriate Government authorities shall have the first right to take such actions; and 

  

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
NIH in writing. If the NIH does not notify the Licensee of its intent to pursue legal action within ninety (90) days, the Licensee shall be free to initiate suit. The NIH shall have a continuing right to
intervene in the suit. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit
if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit, the Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the
motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation.
Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in
deciding whether to bring suit. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or
non-infringement of any of the Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the
Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of 35 U.S.C. Part 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided,
however, that the NIH and appropriate Government authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 9 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(d)	 if the NIH does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the Government
to initiate or to join any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit by motion or any other action of the Licensee, the Licensee shall reimburse the Government
for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If the Licensee elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own
expense. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the NIH
and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 

	 	11.4	 In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement shall be treated as Net Sales and subject to earned royalties. 

 

	 	11.5	 The NIH shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The NIH agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The NIH offers no warranties other than those specified in Article 1. 

 

	 	12.2	 The NIH does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

 

	 	12.3	 THE NIH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 The NIH does not represent that it shall commence legal actions against third parties infringing the
Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the NIH, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: 

 

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors, employees, or third parties of any
Licensed Patent Rights; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials
by the Licensee, or other products or processes developed in connection with or arising out of the Licensed Patent Rights. 

  

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 10 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend to the expiration of the last to expire of the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 

 

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the NIH may terminate this
Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the NIH in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the NIH sixty (60) days written notice to that effect. 

  

	 	13.5	 The NIH shall specifically have the right to terminate or modify, at its option, this Agreement,
if the NIH determines that the Licensee: 

  

	 	(a)	 is not executing the Commercial Development Plan submitted with its request for a license and the
Licensee cannot otherwise demonstrate to the NIH’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve the Practical Application of the
Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks as may be modified under Paragraph 9.2; 

 

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; 

  

	 	(f)	 cannot reasonably satisfy unmet health and safety needs; or 

 

	 	(g)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived. 

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, the NIH shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the NIH shall give written notice to the Licensee providing the Licensee specific notice of, and a [***] opportunity to respond to, the NIH’s concerns as to the items referenced in 13.5(a)-13.5(g). If the Licensee fails to alleviate the NIH’s concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective action
to the NIH’s satisfaction, the NIH may terminate this Agreement. 

  

	 	13.7	 When the public health and safety so require, and after written notice to the Licensee providing the
Licensee a [***] opportunity to respond, the NIH shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 11 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	
under the Licensed Patent Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of
the subject matter of the Licensed Patent Rights. The NIH shall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

 

	 	13.8	 The NIH reserves the right according to 35 U.S.C. 5209(d)(3) to terminate or modify this
Agreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

	 	13.9	 Within thirty (30) days of receipt of written notice of the NIH’s unilateral decision to
modify or terminate this Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated NIH official. The decision of the designated the
NIH official shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be accessible. 

 

	 	13.10	 Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a
final report shall be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the NIH shall become immediately
due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the NIH pursuant to Paragraph 4.3. Unless otherwise specifically provided for
under this Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products or other materials included within the Licensed Patent Rights to the NIH or provide the
NIH with certification of the destruction thereof. The Licensee may not be granted additional NIH licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of the Government to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by the Government or excuse a similar subsequent
failure to perform any of these terms or conditions by the Licensee. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this Agreement
shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. 

 

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 12 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	
commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party.
Agreement notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial
carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.

  

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the Licensee’s Affiliate(s) without the prior written consent of the NIH. The parties agree that the
identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event that the NIH approves a proposed assignment, the Licensee shall pay the
NIH, as an additional royalty, one percent (1%) of the fair market value of any consideration received for any assignment of this Agreement within sixty (60) days of the assignment. 

 

	 	14.8	 The Licensee agrees in its use of any NIH-supplied materials to
comply with all applicable statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States
without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the NIH, in
writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the NIH of research involving human subjects or clinical trials outside of the United States
shall be given no later than sixty (60) days prior to commencement of the research or trials. 

  

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of
these items may require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The
NIH neither represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the NIH’s
patent rights in those countries. 

  

	 	14.11	 By entering into this Agreement, the NIH does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
NIH, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the NIH, the FDA or the HHS or the Government or their employees
in any advertising, promotional, or sales literature without the prior written approval of the NIH. 

  

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated the NIH official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 13 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the
source of the grant. 

  

	 	14.14	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the NIH. 

  

	 	14.15	 Paragraphs 4.3, 8.1, 9.5-9.8,
12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement shall survive termination of this Agreement. 

  

	 	14.16	 The terms and conditions of this Agreement shall, at the NIH’s sole option, be considered by
the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee
and a fully executed original is received by the NIH within sixty (60) days from the date of the NIH’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 14 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 NIH PATENT LICENSE AGREEMENT -EXCLUSIVE 

SIGNATURE PAGE 
 For the NIH: 

 

							
	 /s/ Richard U. Rodriguez
	 		  	 8/28/13
	  	
	 Richard U. Rodriguez
 Director, Division of
Technology Development and Transfer
 Office of Technology Transfer

National Institutes of Health
	 		  	Date                    	  	

 Mailing Address or E-mail Address
for Agreement notices and reports: 
  

			
	 Chief, Monitoring & Enforcement Branch

Office of Technology Transfer
 National Institutes of Health

6011 Executive Boulevard, Suite 325
 Rockville, Maryland
20852-3804 U.S.A.
  

E-mail: LicenseNotices_Reports@mail.nih.gov
	  	

 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any
statements of the Licensee made or referred to in this document are truthful and accurate.): 
 by: 

 

							
	 /s/ Elisabet de los Pinos
	 		  	 9/3/13
	  	
	Signature of Authorized Official	 		  	Date                    	  	
				
	 Elisabet de los Pinos, PhD
	 		  		  	
	Printed Name	 		  		  	
				
	 Founder & CEO
	 		  		  	
	Title	 		  		  	

  

					
	I.    	  	 Official and Mailing Address for Agreement notices:
	  	
			
		  	 Peter Finn.(Rubin & Rudman LLP)
	  	
		  	 Name
	  	
			
		  	 Counsel for Aura Biosciences
	  	
		  	 Title
	  	
			
		  	 Mailing Address
	  	
			
		  	 50 Rowes Wharf
	  	
			
		  	 Boston, MA 02110
	  	
			
		  	  
	  	
			
		  	  
	  	

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 15 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

							
		  	Email Address:	  	pfinn@rubinrudman.com                                  
          	  	
				
	     
	  	Phone:	  	[***]                                     
                                       	  	
				
		  	Fax:	  	[***]                                     
                                       	  	

  

					
	II.	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)
			
		  	 Elisabet de los Pinos, PhD
	  	
		  	Name	  	
			
		  	 Founder & CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge, MA 02140
	  	

  

							
		  	Email Address:	  	[***]                                     
                                       	  	
				
		  	Phone:	  	[***]                                     
                                       	  	
				
	    	  	Fax:	  	[***]                                     
                                       	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 16 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX A - PATENT(S) OR PATENT APPLICATION(S) 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 17 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 18 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX C - ROYALTIES 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 19 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX D - BENCHMARKS AND PERFORMANCE 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 20 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX E - COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 21 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX F - EXAMPLE ROYALTY REPORT 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 22 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX G - ROYALTY PAYMENT OPTIONS 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 23 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 NATIONAL INSTITUTES OF HEALTH 

FIRST AMENDMENT TO L-164-2013/0 

This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”)
within the Department of Health and Human Services (“HHS”), and Aura Biosciences, Inc. having an effective date of September 3, 2013 and having NIH Reference Number L-164-2013/0 (“Agreement”). This First Amendment, having NIH Reference Number L-l64-2013/1, is
made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc. having an office at 85 Bolton Street,
Cambridge, MA 02140 the (“Licensee”). This First Amendment includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Revised Commercial Development Plan), and 3) Attachment 2 (Royalty Payment
Information). 
 WHEREAS, the NIH and the Licensee desire that the Agreement be amended a first time as set forth below in order to
include co-owned intellectual property’ to the Licensed Patent Rights, modify’ the Licensed Field of Use, and modify’ the commercial development plan (Appendix E). 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the Licensee, intending to be bound, hereby
mutually agree to the following: 
  

	 	1)	 The Cover Page’s “Serial Number(s) of Licensed Patent(s) or Patent Application(s)” section and
Appendix A’s Patent(s) or Patent Application(s)’s section shall be deleted and replaced with the following: 

[***] 
  

	 	2)	 Appendix B shall be deleted in its entirety and replaced with the following: 

APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 
  

	 	3)	 Appendix E shall be deleted in its entirety and replaced with the revised commercial development plan in
Attachment 1. 

  

	 	4)	 Within sixty (60) days of the execution of this First Amendment, the Licensee shall pay the
NIH an amendment issue royalty in the sum of [***], and payment options may be found in Attachment 2. 

  

	 	5)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency’ and to give effect to the payment information in such Attachment 2. 

  

	 	6)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	 	7)	 The terms and conditions of this First Amendment shall, al the NIH’s sole option, be
considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this First Amendment, and the First Amendment itself, to be null and void, unless this First Amendment is
executed by the Licensee and a fully’ executed original is received by’ the NIH within sixty (60) day’s from the date of tire NIH’s signature found al the Signature Page. 

 

	 	8)	 This First Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 16	  	

 FIRST AMENDMENT TO
L-164-2013/0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this First Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

					
	
                          
                                         
             
 Richard U. Rodriguez
	  	
                          
  
 Date
	  	
	Director, Division of Technology Development and Transfer	  		  	
	Office of Technology Transfer	  		  	
	National Institutes of Health	  		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

Chief, Monitoring & Enforcement Branch, DTDT 
 Office of
Technology Transfer 
 National Institutes of Health 
 6011
Executive Boulevard, Suite 325 
 Rockville, Maryland 20852-3804 U.S.A. 

E-mail:    LicenseNotices_Reports@mail.nih.gov 

For the Licensee (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made
or referred to in this document are truthful and accurate.): 
  

					
	
                          
                                         
             
 Signature of Authorized Official
	  	
                          
  
 Date
	  	

 Elisabet de los Pinos President and Chief Executive Officer Aura Biosciences Inc. 

 

							
		 	I.	  	Official and Mailing Address for Agreement notices:	  	
				
		 		  	 Elisabet de los Pinos
	  	
		 		  	Name	  	
				
		 		  	 President and Chief Executive Officer
	  	
		 		  	Title	  	
				
		 		  	Mailing Address:	  	
				
		 		  	Aura Biosciences Inc.	  	
		 		  	85 Bolton Street	  	
		 		  	Cambridge, MA 02140	  	
				
		 		  	Email:                [***]	  	
		 		  	Phone:                [***]	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 16	  	

							
		 		  	 With copy to:
	  	
				
		 		  	 Alison Lawton
	  	
		 		  	 Name
	  	
				
		 		  	 Chief Operating Officer
	  	
		 		  	 Title
	  	
				
		 		  	 Mailing Address:
	  	
				
		 		  	 Aura Biosciences Inc.
	  	
		 		  	 85 Bolton Street
	  	
		 		  	 Cambridge, MA 02140
	  	
				
		 		  	 Email:
                [***]
	  	
		 		  	 Phone:
                [***]
	  	
			
		 	 II.
	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):
				
		 		  	 Alison Lawton
	  	
		 		  	 Name
	  	
				
		 		  	 Chief Operating Officer
	  	
		 		  	 Title
	  	
				
		 		  	 Mailing Address:
	  	
				
		 		  	 Aura Biosciences Inc.
	  	
		 		  	 85 Bolton Street
	  	
		 		  	 Cambridge, MA 02140
	  	
				
		 		  	
Email:                [***]
	  	
		 		  	
Phone:                [***]
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 16	  	

 ATTACHMENT 1 - REVISED COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 16	  	

 ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 16	  	

 NATIONAL INSTITUTES OF HEALTH 

SECOND AMENDMENT TO
L-164-2013-0 

[***] 
  

	2)	 Appendix B shall be deleted in its entirety and replaced with the following: 

APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 
  

	3)	 Appendix E- Commercial Development Plan shall be appended with
Attachment 2. 

  

	4)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s)
is/are hereby’ amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 1. 

  

	5)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	6)	 The terms and conditions of this Second Amendment shall, at the NIH’s sole option, be
considered by the NTH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Second Amendment, and the Second Amendment itself, to be null and void, unless this Second Amendment
is executed by the Licensee and a fully executed original is received by the NIH within sixty (60) days from the date of the NIH’s signature found at the Signature Page. 

 

	7)	 This Second Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 21	  	

 SECOND AMENDMENT TO L-164-2013-0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this Second Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

							
	  
 Name: Richard Rodriguez,
M.B.A.
	 		  	  

Date                   
 
	  	
	Title: Associate Director	 		  		  	
	Office: Technology Transfer Center, National Cancer Institute	 		  		  	
	National Institutes of Health	 		  		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration Monitoring & Enforcement Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard,
Suite 325 Rockville, Maryland 20852-3804 U.S.A. 

E-mail:    LicenseNotices_Reports@mail.nih.gov 

For the Licensee Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made or
referred to in this document are truthful and accurate.): 
  

							
	  
 Signature of Authorized
Official
	 		  	  

Date                    
	  	
	Name: Elisabet de los Pinos	 		  		  	
	Title: President and Chief Executive Officer	 		  		  	

  

					
	I.    	  	Official and Mailing Address for Agreement notices:	  	
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and Chief Executive Officer
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 Aura Biosciences Inc.
	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge, MA 02140
	  	
			
		  	  
	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 21	  	

					
	    	  	Email Address:	  	[***]        
			
		  	Phone:	  	[***]        

					
			
		  	Fax:            	  	                                     
                                   

					
			
		  	With copy to:	  	
			
		  	 Michele Keough
	  	
			
		  	Name	  	
			
		  	 Senior Vice President
	  	
			
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 Aura Biosciences Inc
	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	

					
			
		  	Email Address:	  	[***]
			
		  	Phone:	  	[***]
		
	 II.
	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):

  

			
	 Kylie Reynolds
	 	
	Name	 	
		
	VP. Finance	 	
	Title	 	
		
	Mailing Address:	 	
		
	 Aura Bioscience, Inc.
  

85 Bolton Street
	 	
		
	 Cambridge. MA 02140
	 	
		
	  
	 	

  

			
	Email Address:	  	[***]                                     
                                         
                  
		
	Phone:	  	[***]                                     
                                         
                  
		
	Fax:	  	                                    
                                         
                            

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 21	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. $$3801-3812 (civil liability) and
18 U.S.C. $1001 (criminal liability including fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 21	  	

 ATTACHMENT 1 - ROYALTY PAYMENT OPTIONS 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 21	  	

 ATTACHMENT 2 - APPENDIX E ADDENDUM 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 6 of 21	  	

 NATIONAL INSTITUTES OF HEALTH 

THIRD AMENDMENT TO
L-164-2013-0 

Tax ID No: [***] 
 This is the third
amendment (‘Third Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Aura Biosciences, Inc. having
an effective date of September 3, 2013 and having NIH Reference Number L-164-2013-0, its First Amendment
having an effective date of September 28, 2015 and having NIH Reference Number L-164-2013-1, and its Second
Amendment, having an effective date of August 20, 2018 and having NTH Reference Number
L-164-2013-2 (collectively, “Agreement”). This Third Amendment, having NIH Reference Number L-164-2013-3, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc., having an office at 85 Bolton Street, Cambridge MA 02140 (the “Licensee”). This Third Amendment includes, in addition to the
amendments made below, 1) a Signature Page, 2) Attachment 1 (Appendix E- Commercial Development Plan Addition), and Attachment 2 (Royalty Payment Information). 

WHEREAS, the NIH and the Licensee desire that the Agreement be amended a third time as set forth below in order to address combination
products in the Agreement, transfer control of the patent prosecution of the Licensed Patent Rights, update the Benchmarks in Appendix D, and update the Commercial Development Plan in Appendix E. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the Licensee, intending to be bound, hereby
mutually agree to the following: 
  

	1)	 Article 7 shall be deleted in its entirety and replaced with the following: 

 

	 	7.	 PATENT FILING. PROSECUTION. AND MAINTENANCE 

 

	 	7.1	 [***] 

  

	 	7.2	 [***] 

  

	 	7.3	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent Rights,
which comments and suggestions shall be considered by the other party. 

  

	2)	 Article 11 shall be deleted in its entirety and replaced with the following: 

 

	 	11.	 INFRINGEMENT AND PATENT ENFORCEMENT. 

 

	 	11.1	 The NIH and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

 

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for. infringement of presumably valid
claims in the Licensed Patent Rights; 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 17	  	

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights; and 

 

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
NIH in writing. If the NIH does not notify the Licensee of its intent to pursue legal action within ninety (90) days, the Licensee shall be free to initiate suit. The NIH shall have a continuing right to
intervene in the suit. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit
if necessary, to avoid dismissal of the suit. Should the Government be made a party to any suit, the Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the
motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation.
Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in
deciding whether to bring suit. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or noninfringement of any of the
Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee under Paragraph 11.2, pursuant to this Agreement and the
provisions of 35 U.S.C. Part 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights,-provided,
however, that the NIH shall have a continuing right to intervene in the suit; and 

  

	 	(d)	 respond to the legal action within ninety (90) days. The Licensee shall take no action to compel
the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the Government to initiate or to join any suit if necessary, to avoid dismissal of the suit. Should the Government
be made a party to any suit by motion or any other action of the Licensee, the Licensee shall reimburse the Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other
action. If the Licensee elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own expense. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and
progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the
public health in deciding whether to bring suit. 

  

	 	11.4	 In any action under Paragraphs 11.2 or 11.3, the expenses, including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee, which exceeds the expenses incurred with prosecuting or defending any action therein, through court judgment or settlement, shall be treated
as Net Sales and subject to earned royalties. The Licensee shall provide an accounting of any expenses that are deducted from Net Sales under this Paragraph 11.4. 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 17	  	

	 	11.5	 The NIH shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The NIH agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	3)	 Paragraph 14.7 shall be deleted in its entirety and replaced with the following: 

 

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) without the prior written consent of the NIH. The parties agree that the identity of the parties is material to the
formation of this Agreement and that the obligations under this Agreement are nondelegable. [***] 

  

	4)	 Appendix C - Royalties, Paragraph III, shall be deleted in its entirety and replaced with the following:

 The Licensee agrees to pay the NIH earned royalties of [***]. 

 

	5)	 Appendix D - Benchmarks and Performance, shall be deleted in its entirety and replaced with the following:

 The Licensee agrees to the following Benchmarks for its performance under this Agreement and,
within thirty (30) days of achieving a Benchmark, shall notify the NIH that the Benchmark has been achieved. 

[***] 
  

	6)	 Appendix E - Commercial Development Plan shall be appended with Attachment I. 

 

	7)	 [***] 

  

	8)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 2. 

  

	9)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	10)	 The terms and conditions of this Third Amendment shall, at the NIH’s sole option, be
considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Third Amendment, and the Third Amendment itself, to be null and void, unless this Third Amendment is
executed by the Licensee and a fully executed original is received by the NIH within [***] days from the date of the NIH’s signature found at the Signature Page. 

 

	11)	 This Third Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 17	  	

 THIRD AMENDMENT TO L-164-2013-0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this Third Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

					
	Name: Richard U. Rodriguez	 	 	  	 Date

	Title: Associate Director	 		  	
	Office: National Cancer Institute	 		  	
	National Institutes of Health	 		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: [***] 
 For the Licensee (Upon information and belief, the undersigned expressly certifies or affirms that
the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	Signature of Authorized Official	 	 	  	Date

 Name: Elisabet de los Pinos Title: President and CEO 

 

					
	 I.    
	  	 Official and Mailing Address for Agreement notices:
	  	
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	
			
		  	  
	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 17	  	

					
		  	Email Address:	  	[***]                                     
          
			
		  	Phone:	  	[***]                                     
          
			
	    	  	Fax:	  	                                     
                   

					
		
	II.	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	
			
		  	  
	  	
			
		  	  
	  	

  

					
		  	Email Address:	  	[***]                                     
          
			
		  	Phone:	  	[***]                                     
          
			
	    	  	Fax:	  	                                     
                   

Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and
during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C., $$3801-3812 (civil liability) and 18 U.S.C. $1001 (criminal liability including
fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 17	  	

 ATTACHMENT 1 - ADDITION TO APPENDIX E -COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 6 of 17	  	

 ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 
 [***]

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 7 of 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]